Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
less,11120966,MICs,"The MICs at which 90% of the isolates were inhibited of L-036 against methicillin-susceptible staphylococci, Streptococcus pneumoniae including penicillin-resistant organisms, Escherichia coli, Klebsiella pneumoniae, Haemophilus influenzae including ampicillin-resistant organisms, Legionella pneumophila, and Moraxella catarrhalis were equal to or less than 1 microg/ml.","In vitro and in vivo antibacterial activities of L-084, a novel oral carbapenem, against causative organisms of respiratory tract infections. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11120966/),[μg] / [ml],1,12036,DB00535,Cefdinir
,11120966,maximum concentration in serum,"In pharmacokinetics studies of L-084 in lungs of mice, the maximum concentration in serum, half-life, and area under the concentration-time curve of this drug were 9.09 microg/g of tissue, 6.18 h, and 31.0 microg.","In vitro and in vivo antibacterial activities of L-084, a novel oral carbapenem, against causative organisms of respiratory tract infections. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11120966/),[μg] / [g],9.09,12037,DB00535,Cefdinir
,11120966,half-life,"In pharmacokinetics studies of L-084 in lungs of mice, the maximum concentration in serum, half-life, and area under the concentration-time curve of this drug were 9.09 microg/g of tissue, 6.18 h, and 31.0 microg.","In vitro and in vivo antibacterial activities of L-084, a novel oral carbapenem, against causative organisms of respiratory tract infections. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11120966/),h,6.18,12038,DB00535,Cefdinir
,11120966,area under the concentration-time curve,"In pharmacokinetics studies of L-084 in lungs of mice, the maximum concentration in serum, half-life, and area under the concentration-time curve of this drug were 9.09 microg/g of tissue, 6.18 h, and 31.0 microg.","In vitro and in vivo antibacterial activities of L-084, a novel oral carbapenem, against causative organisms of respiratory tract infections. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11120966/),μg,31.0,12039,DB00535,Cefdinir
,2283709,Serum concentrations,"Serum concentrations of CFDN peaked at 0.59 to 1.76 micrograms/ml (mean 1.13 microgram/ml) at 2 hours after dosing of 3 mg/kg in 4 patients, and 0.89 to 2.49 micrograms/ml (mean 1.49 micrograms/ml) 2 or 3 hours after dosing of 6 mg/kg in the other 4 patients.",[Clinical and pharmacokinetic evaluation of cefdinir in children]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2283709/),[μg] / [ml],0.59 to 1.76,19676,DB00535,Cefdinir
,2283709,Serum concentrations,"Serum concentrations of CFDN peaked at 0.59 to 1.76 micrograms/ml (mean 1.13 microgram/ml) at 2 hours after dosing of 3 mg/kg in 4 patients, and 0.89 to 2.49 micrograms/ml (mean 1.49 micrograms/ml) 2 or 3 hours after dosing of 6 mg/kg in the other 4 patients.",[Clinical and pharmacokinetic evaluation of cefdinir in children]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2283709/),[μg] / [ml],1.13,19677,DB00535,Cefdinir
,2283709,Serum concentrations,"Serum concentrations of CFDN peaked at 0.59 to 1.76 micrograms/ml (mean 1.13 microgram/ml) at 2 hours after dosing of 3 mg/kg in 4 patients, and 0.89 to 2.49 micrograms/ml (mean 1.49 micrograms/ml) 2 or 3 hours after dosing of 6 mg/kg in the other 4 patients.",[Clinical and pharmacokinetic evaluation of cefdinir in children]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2283709/),[μg] / [ml],1.49,19678,DB00535,Cefdinir
,2283709,urinary excretion rates,The 8-hour urinary excretion rates were 16.0% to 21.3% (mean 17.4%) in 4 patients given a dose of 3 mg/kg and 10.9 to 21.1% (mean 15.5%) in 4 patients given a dose of 6 mg/kg.,[Clinical and pharmacokinetic evaluation of cefdinir in children]. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2283709/),%,16.0,19679,DB00535,Cefdinir
,2283709,urinary excretion rates,The 8-hour urinary excretion rates were 16.0% to 21.3% (mean 17.4%) in 4 patients given a dose of 3 mg/kg and 10.9 to 21.1% (mean 15.5%) in 4 patients given a dose of 6 mg/kg.,[Clinical and pharmacokinetic evaluation of cefdinir in children]. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2283709/),%,17.4,19680,DB00535,Cefdinir
,2283709,urinary excretion rates,The 8-hour urinary excretion rates were 16.0% to 21.3% (mean 17.4%) in 4 patients given a dose of 3 mg/kg and 10.9 to 21.1% (mean 15.5%) in 4 patients given a dose of 6 mg/kg.,[Clinical and pharmacokinetic evaluation of cefdinir in children]. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2283709/),%,10.9 to 21.1,19681,DB00535,Cefdinir
,2283709,urinary excretion rates,The 8-hour urinary excretion rates were 16.0% to 21.3% (mean 17.4%) in 4 patients given a dose of 3 mg/kg and 10.9 to 21.1% (mean 15.5%) in 4 patients given a dose of 6 mg/kg.,[Clinical and pharmacokinetic evaluation of cefdinir in children]. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2283709/),%,15.5,19682,DB00535,Cefdinir
,23712418,run time,"Following a simple protein precipitation using methanol, chromatographic separation was achieved with a run time of 10 min using a Synergi 4 µ polar-RP 80A column (150 × 2.0 mm, 4 µm) with a mobile phase consisting of 0.1% formic acid in water and methanol (65:35, v/v) at a flow rate of 0.2 mL/min.",Determination of cefdinir levels in rat plasma and urine by high-performance liquid chromatography-tandem mass spectrometry: application to pharmacokinetics after oral and intravenous administration of cefdinir. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23712418/),min,10,23689,DB00535,Cefdinir
,23712418,flow rate,"Following a simple protein precipitation using methanol, chromatographic separation was achieved with a run time of 10 min using a Synergi 4 µ polar-RP 80A column (150 × 2.0 mm, 4 µm) with a mobile phase consisting of 0.1% formic acid in water and methanol (65:35, v/v) at a flow rate of 0.2 mL/min.",Determination of cefdinir levels in rat plasma and urine by high-performance liquid chromatography-tandem mass spectrometry: application to pharmacokinetics after oral and intravenous administration of cefdinir. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23712418/),[ml] / [min],0.2,23690,DB00535,Cefdinir
,1762170,peak plasma level,"After administration, the mean peak plasma level of CFDN was 0.76 micrograms/ml at 4 hours and the mean half-life was 1.77 hours.",[Laboratory and clinical studies of cefdinir 5% and 10% fine granules in pediatric field]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1762170/),[μg] / [ml],0.76,32711,DB00535,Cefdinir
,1762170,half-life,"After administration, the mean peak plasma level of CFDN was 0.76 micrograms/ml at 4 hours and the mean half-life was 1.77 hours.",[Laboratory and clinical studies of cefdinir 5% and 10% fine granules in pediatric field]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1762170/),h,1.77,32712,DB00535,Cefdinir
,1762170,urinary excretion rate,The mean urinary excretion rate of CFDN was 31.5% in the first 12 hours after oral administration.,[Laboratory and clinical studies of cefdinir 5% and 10% fine granules in pediatric field]. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1762170/),%,31.5,32713,DB00535,Cefdinir
,1762170,peak plasma level,After administration of 10% granules the mean peak plasma level of CFDN was 0.73 micrograms/ml at 2 hours and the mean half-life was 1.62 hours.,[Laboratory and clinical studies of cefdinir 5% and 10% fine granules in pediatric field]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1762170/),[μg] / [ml],0.73,32714,DB00535,Cefdinir
,1762170,half-life,After administration of 10% granules the mean peak plasma level of CFDN was 0.73 micrograms/ml at 2 hours and the mean half-life was 1.62 hours.,[Laboratory and clinical studies of cefdinir 5% and 10% fine granules in pediatric field]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1762170/),h,1.62,32715,DB00535,Cefdinir
,1762170,peak serum level,The peak serum level obtained after administration of CFDN 100 mg capsule was 0.91 micrograms/ml at 2 hours and the half-life was 1.08 hours.,[Laboratory and clinical studies of cefdinir 5% and 10% fine granules in pediatric field]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1762170/),[μg] / [ml],0.91,32716,DB00535,Cefdinir
,1762170,half-life,The peak serum level obtained after administration of CFDN 100 mg capsule was 0.91 micrograms/ml at 2 hours and the half-life was 1.08 hours.,[Laboratory and clinical studies of cefdinir 5% and 10% fine granules in pediatric field]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1762170/),h,1.08,32717,DB00535,Cefdinir
,1762170,urinary excretion rate,The mean urinary excretion rate obtained with CFDN 10% fine granules was 26.2% in the first 8 hours after oral administration and the urinary excretion rate obtained with CFDN 100 mg capsule was 19.7% in the first 12 hours after oral administration.,[Laboratory and clinical studies of cefdinir 5% and 10% fine granules in pediatric field]. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1762170/),%,26.2,32718,DB00535,Cefdinir
,1762170,urinary excretion rate,The mean urinary excretion rate obtained with CFDN 10% fine granules was 26.2% in the first 8 hours after oral administration and the urinary excretion rate obtained with CFDN 100 mg capsule was 19.7% in the first 12 hours after oral administration.,[Laboratory and clinical studies of cefdinir 5% and 10% fine granules in pediatric field]. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1762170/),%,19.7,32719,DB00535,Cefdinir
,1762162,Cmax,"Cmax was 0.81 +/- 0.38 microgram/ml, T 1/2 was 2.31 +/- 0.77 hours.",[Clinical evaluation of cefdinir 10% granules in children]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1762162/),[μg] / [ml],0.81,33265,DB00535,Cefdinir
,1762162,T 1/2,"Cmax was 0.81 +/- 0.38 microgram/ml, T 1/2 was 2.31 +/- 0.77 hours.",[Clinical evaluation of cefdinir 10% granules in children]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1762162/),h,2.31,33266,DB00535,Cefdinir
,9661010,maximum plasma concentration (Cmax),"In the test without dialysis, the maximum plasma concentration (Cmax) was 2.36 +/- 0.53 micrograms/ml (mean +/- standard deviation) and the time to Cmax was 9.00 +/- 2.45 h.","Pharmacokinetic study of an oral cephalosporin, cefdinir, in hemodialysis patients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9661010/),[μg] / [ml],2.36,39975,DB00535,Cefdinir
,9661010,time to Cmax,"In the test without dialysis, the maximum plasma concentration (Cmax) was 2.36 +/- 0.53 micrograms/ml (mean +/- standard deviation) and the time to Cmax was 9.00 +/- 2.45 h.","Pharmacokinetic study of an oral cephalosporin, cefdinir, in hemodialysis patients. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9661010/),h,9.00,39976,DB00535,Cefdinir
,9661010,terminal elimination half-life (t1/2),"The terminal elimination half-life (t1/2) and area under the concentration-time curve (AUC) were 16.95 +/- 1.20 h and 69.05 +/- 14.84 micrograms.h/ml, respectively.","Pharmacokinetic study of an oral cephalosporin, cefdinir, in hemodialysis patients. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9661010/),h,16.95,39977,DB00535,Cefdinir
,9661010,area under the concentration-time curve (AUC),"The terminal elimination half-life (t1/2) and area under the concentration-time curve (AUC) were 16.95 +/- 1.20 h and 69.05 +/- 14.84 micrograms.h/ml, respectively.","Pharmacokinetic study of an oral cephalosporin, cefdinir, in hemodialysis patients. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9661010/),[h·μg] / [ml],69.05,39978,DB00535,Cefdinir
,9661010,fractional removal,The fractional removal of cefdinir by hemodialysis was 61%.,"Pharmacokinetic study of an oral cephalosporin, cefdinir, in hemodialysis patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9661010/),%,61,39979,DB00535,Cefdinir
,2086816,Cmax,Plasma concentration peaked at 3-4 hours after administration of 3 mg/kg of CFDN with Cmax ranging from 0.57-0.89 microgram/ml except 1 case in which the absorption of the drug was poor.,[Pharmacokinetic and clinical studies on cefdinir fine granules in children]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2086816/),[μg] / [ml],0.57-0.89,40533,DB00535,Cefdinir
,2086816,Recovery rates,"Recovery rates in urine averaged at 13.4%, with a large individual variation.",[Pharmacokinetic and clinical studies on cefdinir fine granules in children]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2086816/),%,13.4,40534,DB00535,Cefdinir
,2086819,peak values,"1. Mean plasma peak levels of CFDN were observed at 3 hours after administration in both the 3 mg/kg and 6 mg/kg groups with mean peak values of 0.68 and 1.35 micrograms/ml, respectively.",[Pharmacokinetics and clinical effects of cefdinir 5% fine granules in pediatrics]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2086819/),[μg] / [ml],0.68,54746,DB00535,Cefdinir
,2086819,peak values,"1. Mean plasma peak levels of CFDN were observed at 3 hours after administration in both the 3 mg/kg and 6 mg/kg groups with mean peak values of 0.68 and 1.35 micrograms/ml, respectively.",[Pharmacokinetics and clinical effects of cefdinir 5% fine granules in pediatrics]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2086819/),[μg] / [ml],1.35,54747,DB00535,Cefdinir
,2086819,half-lives,"Mean half-lives were 2.06 hours in the 3 mg/kg group and 1.61 hours in the 6 mg/kg group, and mean AUCs were 3.5 in the former and 6.5 micrograms.hr/ml in the latter.",[Pharmacokinetics and clinical effects of cefdinir 5% fine granules in pediatrics]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2086819/),h,2.06,54748,DB00535,Cefdinir
,2086819,half-lives,"Mean half-lives were 2.06 hours in the 3 mg/kg group and 1.61 hours in the 6 mg/kg group, and mean AUCs were 3.5 in the former and 6.5 micrograms.hr/ml in the latter.",[Pharmacokinetics and clinical effects of cefdinir 5% fine granules in pediatrics]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2086819/),h,1.61,54749,DB00535,Cefdinir
,2086819,AUCs,"Mean half-lives were 2.06 hours in the 3 mg/kg group and 1.61 hours in the 6 mg/kg group, and mean AUCs were 3.5 in the former and 6.5 micrograms.hr/ml in the latter.",[Pharmacokinetics and clinical effects of cefdinir 5% fine granules in pediatrics]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2086819/),[h·μg] / [ml],3.5,54750,DB00535,Cefdinir
,2086819,AUCs,"Mean half-lives were 2.06 hours in the 3 mg/kg group and 1.61 hours in the 6 mg/kg group, and mean AUCs were 3.5 in the former and 6.5 micrograms.hr/ml in the latter.",[Pharmacokinetics and clinical effects of cefdinir 5% fine granules in pediatrics]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2086819/),[h·μg] / [ml],6.5,54751,DB00535,Cefdinir
,2086819,plasma peak levels,"Mean plasma peak levels of CFDN were 0.71 and 1.31 micrograms/ml in the doses of 3 mg/kg and 6 mg/kg, respectively.",[Pharmacokinetics and clinical effects of cefdinir 5% fine granules in pediatrics]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2086819/),[μg] / [ml],0.71,54752,DB00535,Cefdinir
,2086819,plasma peak levels,"Mean plasma peak levels of CFDN were 0.71 and 1.31 micrograms/ml in the doses of 3 mg/kg and 6 mg/kg, respectively.",[Pharmacokinetics and clinical effects of cefdinir 5% fine granules in pediatrics]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2086819/),[μg] / [ml],1.31,54753,DB00535,Cefdinir
,2086819,Half-lives,"Half-lives were 1.39-2.90 hours in the 3 mg/kg group and 1.21-1.48 hours in the 6 mg/kg group, with AUCs of 3.4-3.7 and 4.1-7.5 micrograms.hr/ml, respectively.",[Pharmacokinetics and clinical effects of cefdinir 5% fine granules in pediatrics]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2086819/),h,1.39-2.90,54754,DB00535,Cefdinir
,2086819,Half-lives,"Half-lives were 1.39-2.90 hours in the 3 mg/kg group and 1.21-1.48 hours in the 6 mg/kg group, with AUCs of 3.4-3.7 and 4.1-7.5 micrograms.hr/ml, respectively.",[Pharmacokinetics and clinical effects of cefdinir 5% fine granules in pediatrics]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2086819/),h,1.21-1.48,54755,DB00535,Cefdinir
,2086819,AUCs,"Half-lives were 1.39-2.90 hours in the 3 mg/kg group and 1.21-1.48 hours in the 6 mg/kg group, with AUCs of 3.4-3.7 and 4.1-7.5 micrograms.hr/ml, respectively.",[Pharmacokinetics and clinical effects of cefdinir 5% fine granules in pediatrics]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2086819/),[h·μg] / [ml],3.4-3.7,54756,DB00535,Cefdinir
,2086819,AUCs,"Half-lives were 1.39-2.90 hours in the 3 mg/kg group and 1.21-1.48 hours in the 6 mg/kg group, with AUCs of 3.4-3.7 and 4.1-7.5 micrograms.hr/ml, respectively.",[Pharmacokinetics and clinical effects of cefdinir 5% fine granules in pediatrics]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2086819/),[h·μg] / [ml],4.1-7.5,54757,DB00535,Cefdinir
,1762171,half-life,Average plasma concentrations peaked at 4 hours after administration at 0.99 micrograms/ml with a half-life of 2.12 hours.,"[Pharmacokinetic, bacteriological and clinical studies on cefdinir fine granules in the field of pediatrics]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1762171/),h,2.12,88287,DB00535,Cefdinir
,1762171,first 24-hour,The first 24-hour urinary recovery rates of CFDN in 3 children averaged 22.0%.,"[Pharmacokinetic, bacteriological and clinical studies on cefdinir fine granules in the field of pediatrics]. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1762171/),%,22.0,88288,DB00535,Cefdinir
,1762171,urinary recovery rates,The first 24-hour urinary recovery rates of CFDN in 3 children averaged 22.0%.,"[Pharmacokinetic, bacteriological and clinical studies on cefdinir fine granules in the field of pediatrics]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1762171/),%,22.0,88289,DB00535,Cefdinir
,1762171,overall efficacy rate,"Clinical effects were excellent in 16, good in 7 and not evaluable in 1, with an overall efficacy rate of 100%.","[Pharmacokinetic, bacteriological and clinical studies on cefdinir fine granules in the field of pediatrics]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1762171/),,100,88290,DB00535,Cefdinir
,1762171,eradication rate,"Bacteriological effects were rated as ""eradicated"" for 19 strains, ""unchanged"" for 4 with an eradication rate of 82.6%.","[Pharmacokinetic, bacteriological and clinical studies on cefdinir fine granules in the field of pediatrics]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1762171/),%,82.6,88291,DB00535,Cefdinir
,1495194,Tmax,"Tmax, Cmax, T 1/2 and urinary recovery rate (0-8 hours) following the administration before meal were 2.00 +/- 0.00 hours, 1.14 +/- 0.11 micrograms/ml, 1.63 +/- 0.14 hours and 23.68 +/- 2.92%, respectively, Tmax, Cmax, T1/2 and urinary recovery rate following the administration after meal were 3.67 +/- 0.33 hours, 0.71 +/- 0.06 micrograms/ml, 2.18 +/- 0.16 hours and 21.76 +/- 2.36%, respectively.",[Pharmacokinetic studies on oral antibiotics in pediatrics. V. A pharmacokinetic study on cefdinir in pediatrics]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1495194/),h,2.00,89421,DB00535,Cefdinir
,1495194,urinary recovery rate,"Tmax, Cmax, T 1/2 and urinary recovery rate (0-8 hours) following the administration before meal were 2.00 +/- 0.00 hours, 1.14 +/- 0.11 micrograms/ml, 1.63 +/- 0.14 hours and 23.68 +/- 2.92%, respectively, Tmax, Cmax, T1/2 and urinary recovery rate following the administration after meal were 3.67 +/- 0.33 hours, 0.71 +/- 0.06 micrograms/ml, 2.18 +/- 0.16 hours and 21.76 +/- 2.36%, respectively.",[Pharmacokinetic studies on oral antibiotics in pediatrics. V. A pharmacokinetic study on cefdinir in pediatrics]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1495194/),%,23.68,89422,DB00535,Cefdinir
,1495194,Tmax,"Tmax, Cmax, T 1/2 and urinary recovery rate (0-8 hours) following the administration before meal were 2.00 +/- 0.00 hours, 1.14 +/- 0.11 micrograms/ml, 1.63 +/- 0.14 hours and 23.68 +/- 2.92%, respectively, Tmax, Cmax, T1/2 and urinary recovery rate following the administration after meal were 3.67 +/- 0.33 hours, 0.71 +/- 0.06 micrograms/ml, 2.18 +/- 0.16 hours and 21.76 +/- 2.36%, respectively.",[Pharmacokinetic studies on oral antibiotics in pediatrics. V. A pharmacokinetic study on cefdinir in pediatrics]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1495194/),h,3.67,89423,DB00535,Cefdinir
,1495194,Cmax,"Tmax, Cmax, T 1/2 and urinary recovery rate (0-8 hours) following the administration before meal were 2.00 +/- 0.00 hours, 1.14 +/- 0.11 micrograms/ml, 1.63 +/- 0.14 hours and 23.68 +/- 2.92%, respectively, Tmax, Cmax, T1/2 and urinary recovery rate following the administration after meal were 3.67 +/- 0.33 hours, 0.71 +/- 0.06 micrograms/ml, 2.18 +/- 0.16 hours and 21.76 +/- 2.36%, respectively.",[Pharmacokinetic studies on oral antibiotics in pediatrics. V. A pharmacokinetic study on cefdinir in pediatrics]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1495194/),[μg] / [ml],0.71,89424,DB00535,Cefdinir
,1495194,Cmax,"Tmax, Cmax, T 1/2 and urinary recovery rate (0-8 hours) following the administration before meal were 2.00 +/- 0.00 hours, 1.14 +/- 0.11 micrograms/ml, 1.63 +/- 0.14 hours and 23.68 +/- 2.92%, respectively, Tmax, Cmax, T1/2 and urinary recovery rate following the administration after meal were 3.67 +/- 0.33 hours, 0.71 +/- 0.06 micrograms/ml, 2.18 +/- 0.16 hours and 21.76 +/- 2.36%, respectively.",[Pharmacokinetic studies on oral antibiotics in pediatrics. V. A pharmacokinetic study on cefdinir in pediatrics]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1495194/),h,2.18,89425,DB00535,Cefdinir
,1495194,T1/2,"Tmax, Cmax, T 1/2 and urinary recovery rate (0-8 hours) following the administration before meal were 2.00 +/- 0.00 hours, 1.14 +/- 0.11 micrograms/ml, 1.63 +/- 0.14 hours and 23.68 +/- 2.92%, respectively, Tmax, Cmax, T1/2 and urinary recovery rate following the administration after meal were 3.67 +/- 0.33 hours, 0.71 +/- 0.06 micrograms/ml, 2.18 +/- 0.16 hours and 21.76 +/- 2.36%, respectively.",[Pharmacokinetic studies on oral antibiotics in pediatrics. V. A pharmacokinetic study on cefdinir in pediatrics]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1495194/),[μg] / [ml],0.71,89426,DB00535,Cefdinir
,1495194,T1/2,"Tmax, Cmax, T 1/2 and urinary recovery rate (0-8 hours) following the administration before meal were 2.00 +/- 0.00 hours, 1.14 +/- 0.11 micrograms/ml, 1.63 +/- 0.14 hours and 23.68 +/- 2.92%, respectively, Tmax, Cmax, T1/2 and urinary recovery rate following the administration after meal were 3.67 +/- 0.33 hours, 0.71 +/- 0.06 micrograms/ml, 2.18 +/- 0.16 hours and 21.76 +/- 2.36%, respectively.",[Pharmacokinetic studies on oral antibiotics in pediatrics. V. A pharmacokinetic study on cefdinir in pediatrics]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1495194/),h,2.18,89427,DB00535,Cefdinir
,1495194,urinary recovery rate,"Tmax, Cmax, T 1/2 and urinary recovery rate (0-8 hours) following the administration before meal were 2.00 +/- 0.00 hours, 1.14 +/- 0.11 micrograms/ml, 1.63 +/- 0.14 hours and 23.68 +/- 2.92%, respectively, Tmax, Cmax, T1/2 and urinary recovery rate following the administration after meal were 3.67 +/- 0.33 hours, 0.71 +/- 0.06 micrograms/ml, 2.18 +/- 0.16 hours and 21.76 +/- 2.36%, respectively.",[Pharmacokinetic studies on oral antibiotics in pediatrics. V. A pharmacokinetic study on cefdinir in pediatrics]. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1495194/),%,21.76,89428,DB00535,Cefdinir
,1495194,Tmax,"Tmax, Cmax, T1/2 and urinary recovery rate following the administration before meal were 2.11 +/- 0.11 hours, 0.98 +/- 0.14 micrograms/ml, 1.71 +/- 0.23 hours and 23.60 +/- 1.72%, respectively, Tmax, Cmax, T1/2 and urinary recovery rate following the administration after meal were 3.33 +/- 0.42 hours, 0.47 +/- 0.14 micrograms/ml, 2.35 +/- 0.27 hours and 12.24 +/- 2.02%, respectively.",[Pharmacokinetic studies on oral antibiotics in pediatrics. V. A pharmacokinetic study on cefdinir in pediatrics]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1495194/),h,2.11,89429,DB00535,Cefdinir
,1495194,urinary recovery rate,"Tmax, Cmax, T1/2 and urinary recovery rate following the administration before meal were 2.11 +/- 0.11 hours, 0.98 +/- 0.14 micrograms/ml, 1.71 +/- 0.23 hours and 23.60 +/- 1.72%, respectively, Tmax, Cmax, T1/2 and urinary recovery rate following the administration after meal were 3.33 +/- 0.42 hours, 0.47 +/- 0.14 micrograms/ml, 2.35 +/- 0.27 hours and 12.24 +/- 2.02%, respectively.",[Pharmacokinetic studies on oral antibiotics in pediatrics. V. A pharmacokinetic study on cefdinir in pediatrics]. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1495194/),%,23.60,89430,DB00535,Cefdinir
,1495194,Tmax,"Tmax, Cmax, T1/2 and urinary recovery rate following the administration before meal were 2.11 +/- 0.11 hours, 0.98 +/- 0.14 micrograms/ml, 1.71 +/- 0.23 hours and 23.60 +/- 1.72%, respectively, Tmax, Cmax, T1/2 and urinary recovery rate following the administration after meal were 3.33 +/- 0.42 hours, 0.47 +/- 0.14 micrograms/ml, 2.35 +/- 0.27 hours and 12.24 +/- 2.02%, respectively.",[Pharmacokinetic studies on oral antibiotics in pediatrics. V. A pharmacokinetic study on cefdinir in pediatrics]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1495194/),h,3.33,89431,DB00535,Cefdinir
,1495194,Cmax,"Tmax, Cmax, T1/2 and urinary recovery rate following the administration before meal were 2.11 +/- 0.11 hours, 0.98 +/- 0.14 micrograms/ml, 1.71 +/- 0.23 hours and 23.60 +/- 1.72%, respectively, Tmax, Cmax, T1/2 and urinary recovery rate following the administration after meal were 3.33 +/- 0.42 hours, 0.47 +/- 0.14 micrograms/ml, 2.35 +/- 0.27 hours and 12.24 +/- 2.02%, respectively.",[Pharmacokinetic studies on oral antibiotics in pediatrics. V. A pharmacokinetic study on cefdinir in pediatrics]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1495194/),[μg] / [ml],0.47,89432,DB00535,Cefdinir
,1495194,Cmax,"Tmax, Cmax, T1/2 and urinary recovery rate following the administration before meal were 2.11 +/- 0.11 hours, 0.98 +/- 0.14 micrograms/ml, 1.71 +/- 0.23 hours and 23.60 +/- 1.72%, respectively, Tmax, Cmax, T1/2 and urinary recovery rate following the administration after meal were 3.33 +/- 0.42 hours, 0.47 +/- 0.14 micrograms/ml, 2.35 +/- 0.27 hours and 12.24 +/- 2.02%, respectively.",[Pharmacokinetic studies on oral antibiotics in pediatrics. V. A pharmacokinetic study on cefdinir in pediatrics]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1495194/),h,2.35,89433,DB00535,Cefdinir
,1495194,T1/2,"Tmax, Cmax, T1/2 and urinary recovery rate following the administration before meal were 2.11 +/- 0.11 hours, 0.98 +/- 0.14 micrograms/ml, 1.71 +/- 0.23 hours and 23.60 +/- 1.72%, respectively, Tmax, Cmax, T1/2 and urinary recovery rate following the administration after meal were 3.33 +/- 0.42 hours, 0.47 +/- 0.14 micrograms/ml, 2.35 +/- 0.27 hours and 12.24 +/- 2.02%, respectively.",[Pharmacokinetic studies on oral antibiotics in pediatrics. V. A pharmacokinetic study on cefdinir in pediatrics]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1495194/),[μg] / [ml],0.47,89434,DB00535,Cefdinir
,1495194,urinary recovery rate,"Tmax, Cmax, T1/2 and urinary recovery rate following the administration before meal were 2.11 +/- 0.11 hours, 0.98 +/- 0.14 micrograms/ml, 1.71 +/- 0.23 hours and 23.60 +/- 1.72%, respectively, Tmax, Cmax, T1/2 and urinary recovery rate following the administration after meal were 3.33 +/- 0.42 hours, 0.47 +/- 0.14 micrograms/ml, 2.35 +/- 0.27 hours and 12.24 +/- 2.02%, respectively.",[Pharmacokinetic studies on oral antibiotics in pediatrics. V. A pharmacokinetic study on cefdinir in pediatrics]. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1495194/),%,12.24,89435,DB00535,Cefdinir
,1495194,Tmax,"Tmax, Cmax, and T1/2 following the administration before meal were 4.00 +/- 0.62 hours, 0.61 +/- 0.13 micrograms/ml and 3.14 +/- 0.62 hours, respectively, Tmax, Cmax and T 1/2 following the administration after meal were 3.75 +/- 0.25 hours, 0.79 +/- 0.13 micrograms/ml and 2.44 +/- 0.42 hours, respectively.",[Pharmacokinetic studies on oral antibiotics in pediatrics. V. A pharmacokinetic study on cefdinir in pediatrics]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1495194/),h,4.00,89436,DB00535,Cefdinir
,1495194,Cmax,"Tmax, Cmax, and T1/2 following the administration before meal were 4.00 +/- 0.62 hours, 0.61 +/- 0.13 micrograms/ml and 3.14 +/- 0.62 hours, respectively, Tmax, Cmax and T 1/2 following the administration after meal were 3.75 +/- 0.25 hours, 0.79 +/- 0.13 micrograms/ml and 2.44 +/- 0.42 hours, respectively.",[Pharmacokinetic studies on oral antibiotics in pediatrics. V. A pharmacokinetic study on cefdinir in pediatrics]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1495194/),[μg] / [ml],0.61,89437,DB00535,Cefdinir
,1495194,T1/2,"Tmax, Cmax, and T1/2 following the administration before meal were 4.00 +/- 0.62 hours, 0.61 +/- 0.13 micrograms/ml and 3.14 +/- 0.62 hours, respectively, Tmax, Cmax and T 1/2 following the administration after meal were 3.75 +/- 0.25 hours, 0.79 +/- 0.13 micrograms/ml and 2.44 +/- 0.42 hours, respectively.",[Pharmacokinetic studies on oral antibiotics in pediatrics. V. A pharmacokinetic study on cefdinir in pediatrics]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1495194/),h,3.14,89438,DB00535,Cefdinir
,1495194,Tmax,"Tmax, Cmax, and T1/2 following the administration before meal were 4.00 +/- 0.62 hours, 0.61 +/- 0.13 micrograms/ml and 3.14 +/- 0.62 hours, respectively, Tmax, Cmax and T 1/2 following the administration after meal were 3.75 +/- 0.25 hours, 0.79 +/- 0.13 micrograms/ml and 2.44 +/- 0.42 hours, respectively.",[Pharmacokinetic studies on oral antibiotics in pediatrics. V. A pharmacokinetic study on cefdinir in pediatrics]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1495194/),h,3.75,89439,DB00535,Cefdinir
,1495194,Cmax,"Tmax, Cmax, and T1/2 following the administration before meal were 4.00 +/- 0.62 hours, 0.61 +/- 0.13 micrograms/ml and 3.14 +/- 0.62 hours, respectively, Tmax, Cmax and T 1/2 following the administration after meal were 3.75 +/- 0.25 hours, 0.79 +/- 0.13 micrograms/ml and 2.44 +/- 0.42 hours, respectively.",[Pharmacokinetic studies on oral antibiotics in pediatrics. V. A pharmacokinetic study on cefdinir in pediatrics]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1495194/),[μg] / [ml],0.79,89440,DB00535,Cefdinir
,1495194,T 1/2,"Tmax, Cmax, and T1/2 following the administration before meal were 4.00 +/- 0.62 hours, 0.61 +/- 0.13 micrograms/ml and 3.14 +/- 0.62 hours, respectively, Tmax, Cmax and T 1/2 following the administration after meal were 3.75 +/- 0.25 hours, 0.79 +/- 0.13 micrograms/ml and 2.44 +/- 0.42 hours, respectively.",[Pharmacokinetic studies on oral antibiotics in pediatrics. V. A pharmacokinetic study on cefdinir in pediatrics]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1495194/),h,2.44,89441,DB00535,Cefdinir
,2283712,urinary recovery rate,The 8-hour urinary recovery rate was 18.8%.,[Laboratory and clinical studies on cefdinir in pediatric field]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2283712/),h,8,93287,DB00535,Cefdinir
,2283712,urinary recovery rate,The 8-hour urinary recovery rate was 18.8%.,[Laboratory and clinical studies on cefdinir in pediatric field]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2283712/),%,18.8,93288,DB00535,Cefdinir
,2283712,overall,"3. Bacteriologically, 18 of the 19 strains of causative organisms identified were eradicated, with an overall bacteriological eradication rate of 94.7%.",[Laboratory and clinical studies on cefdinir in pediatric field]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2283712/),%,94.7,93289,DB00535,Cefdinir
,1495197,peak values,"1. Mean plasma peak levels of CFDN were observed at 2 hours after administration in the before-meal group and 4 or 5 hours after administration in the after-meal group mean peak values of 0.88 and 0.50 micrograms/ml, respectively.",[Pharmacokinetics and clinical effects of cefdinir 10% fine granules in pediatrics]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1495197/),[μg] / [ml],0.88,97102,DB00535,Cefdinir
,1495197,peak values,"1. Mean plasma peak levels of CFDN were observed at 2 hours after administration in the before-meal group and 4 or 5 hours after administration in the after-meal group mean peak values of 0.88 and 0.50 micrograms/ml, respectively.",[Pharmacokinetics and clinical effects of cefdinir 10% fine granules in pediatrics]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1495197/),[μg] / [ml],0.50,97103,DB00535,Cefdinir
,1495197,half-lives,"Mean half-lives were 1.61 hours in the before-meal group and 2.54 hours in the after-meal group, and mean AUCs were 4.24 in the former and 3.59 micrograms.hr/ml in the latter.",[Pharmacokinetics and clinical effects of cefdinir 10% fine granules in pediatrics]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1495197/),h,1.61,97104,DB00535,Cefdinir
,1495197,half-lives,"Mean half-lives were 1.61 hours in the before-meal group and 2.54 hours in the after-meal group, and mean AUCs were 4.24 in the former and 3.59 micrograms.hr/ml in the latter.",[Pharmacokinetics and clinical effects of cefdinir 10% fine granules in pediatrics]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1495197/),h,2.54,97105,DB00535,Cefdinir
,1495197,AUCs,"Mean half-lives were 1.61 hours in the before-meal group and 2.54 hours in the after-meal group, and mean AUCs were 4.24 in the former and 3.59 micrograms.hr/ml in the latter.",[Pharmacokinetics and clinical effects of cefdinir 10% fine granules in pediatrics]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1495197/),[h·μg] / [ml],4.24,97106,DB00535,Cefdinir
,1495197,AUCs,"Mean half-lives were 1.61 hours in the before-meal group and 2.54 hours in the after-meal group, and mean AUCs were 4.24 in the former and 3.59 micrograms.hr/ml in the latter.",[Pharmacokinetics and clinical effects of cefdinir 10% fine granules in pediatrics]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1495197/),[h·μg] / [ml],3.59,97107,DB00535,Cefdinir
,1495197,urinary,"2. Mean urinary peak concentrations of CFDN were observed during 2-4 hours after dosing in the before-meal group and during 6-8 hours in the after-meal group with values of 93.3 and 44.8 micrograms/ml, respectively, in cases for which plasma concentrations of drugs were determined.",[Pharmacokinetics and clinical effects of cefdinir 10% fine granules in pediatrics]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1495197/),[μg] / [ml],93.3,97108,DB00535,Cefdinir
,1495197,urinary,"2. Mean urinary peak concentrations of CFDN were observed during 2-4 hours after dosing in the before-meal group and during 6-8 hours in the after-meal group with values of 93.3 and 44.8 micrograms/ml, respectively, in cases for which plasma concentrations of drugs were determined.",[Pharmacokinetics and clinical effects of cefdinir 10% fine granules in pediatrics]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1495197/),[μg] / [ml],44.8,97109,DB00535,Cefdinir
,1495197,peak concentrations,"2. Mean urinary peak concentrations of CFDN were observed during 2-4 hours after dosing in the before-meal group and during 6-8 hours in the after-meal group with values of 93.3 and 44.8 micrograms/ml, respectively, in cases for which plasma concentrations of drugs were determined.",[Pharmacokinetics and clinical effects of cefdinir 10% fine granules in pediatrics]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1495197/),[μg] / [ml],93.3,97110,DB00535,Cefdinir
,1495197,peak concentrations,"2. Mean urinary peak concentrations of CFDN were observed during 2-4 hours after dosing in the before-meal group and during 6-8 hours in the after-meal group with values of 93.3 and 44.8 micrograms/ml, respectively, in cases for which plasma concentrations of drugs were determined.",[Pharmacokinetics and clinical effects of cefdinir 10% fine granules in pediatrics]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1495197/),[μg] / [ml],44.8,97111,DB00535,Cefdinir
,1495197,urinary recovery rates,"Mean urinary recovery rates during the first 8 hours after administration in the before- and after-meal groups were 16.6 and 13.4%, respectively.",[Pharmacokinetics and clinical effects of cefdinir 10% fine granules in pediatrics]. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1495197/),%,16.6,97112,DB00535,Cefdinir
,1495197,urinary recovery rates,"Mean urinary recovery rates during the first 8 hours after administration in the before- and after-meal groups were 16.6 and 13.4%, respectively.",[Pharmacokinetics and clinical effects of cefdinir 10% fine granules in pediatrics]. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1495197/),%,13.4,97113,DB00535,Cefdinir
,1495197,era,"4. Good bacteriological effects were also obtained against 2 strains of Streptococcus pyogenes, 2 strains of Escherichia coli and 1 strain of Haemophilus influenzae with an eradication rate of 100%.",[Pharmacokinetics and clinical effects of cefdinir 10% fine granules in pediatrics]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1495197/),,100,97114,DB00535,Cefdinir
,21782531,flow rate,"The mobile phase, methanol/acetonitrile (50/50, v/v):0.05% trifluoroacetic acid (19:81, v/v), operated at 50°C column oven temperature was pumped at a flow rate of 2.0 mL min(-1) and the column eluents were monitored at a wavelength of 285 nm.","Simultaneous determination of cefdinir and cefixime in human plasma by RP-HPLC/UV detection method: Method development, optimization, validation, and its application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21782531/),[ml] / [min],2.0,100939,DB00535,Cefdinir
,7745814,MICs,MICs of SY5555 for Gram-positive cocci ranged from 0.05 to 0.10 microgram/ml against 10 strains of Staphylococcus aureus.,"[Pharmacokinetic, bacteriological and clinical studies of SY5555 in the pediatric field]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7745814/),[μg] / [ml],0.05 to 0.10,114918,DB00535,Cefdinir
<,7745814,MIC,"The MIC was < or = 0.025 microgram/ml against one strain of Streptococcus pyogenes, and MICs were from < or = 0.025 to 0.39 microgram/ml against Streptococcus pneumoniae.","[Pharmacokinetic, bacteriological and clinical studies of SY5555 in the pediatric field]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7745814/),[μg] / [ml],0.025,114919,DB00535,Cefdinir
<,7745814,MICs,"The MIC was < or = 0.025 microgram/ml against one strain of Streptococcus pyogenes, and MICs were from < or = 0.025 to 0.39 microgram/ml against Streptococcus pneumoniae.","[Pharmacokinetic, bacteriological and clinical studies of SY5555 in the pediatric field]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7745814/),[μg] / [ml],0,114920,DB00535,Cefdinir
,7745814,MICs,"MICs of SY5555 for Gram-negative bacilli were 0.39 and 6.25 micrograms/ml against Haemophilus influenzae, and these values were equivalent to those of the other drugs, except CPDX.","[Pharmacokinetic, bacteriological and clinical studies of SY5555 in the pediatric field]. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7745814/),[μg] / [ml],0.39,114921,DB00535,Cefdinir
,7745814,MICs,"MICs of SY5555 for Gram-negative bacilli were 0.39 and 6.25 micrograms/ml against Haemophilus influenzae, and these values were equivalent to those of the other drugs, except CPDX.","[Pharmacokinetic, bacteriological and clinical studies of SY5555 in the pediatric field]. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7745814/),[μg] / [ml],6.25,114922,DB00535,Cefdinir
,7745814,MIC,"The MIC of SY5555 was 0.39 microgram/ml against 2 strains of Escherichia coli, and this value was equivalent or superior to those of CVA/AMPC and CCL, similar or inferior to those of CPDX and CFDN, and inferior to that of CTM.","[Pharmacokinetic, bacteriological and clinical studies of SY5555 in the pediatric field]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7745814/),[μg] / [ml],0.39,114923,DB00535,Cefdinir
,7745814,MIC,The MIC of SY5555 was 0.78 microgram/ml against all of the strains.,"[Pharmacokinetic, bacteriological and clinical studies of SY5555 in the pediatric field]. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7745814/),[μg] / [ml],0.78,114924,DB00535,Cefdinir
<,7745814,MIC,"CCL, CTM, CPDX, CFDN, ABPC, IPM and EM, and the MIC of SY5555 was < or = 0.025 microgram/ml or 0.05 microgram/ml and these values were equivalent or superior to those of the 7 reference drugs.","[Pharmacokinetic, bacteriological and clinical studies of SY5555 in the pediatric field]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7745814/),[μg] / [ml],0.025,114925,DB00535,Cefdinir
,7745814,MIC,"CCL, CTM, CPDX, CFDN, ABPC, IPM and EM, and the MIC of SY5555 was < or = 0.025 microgram/ml or 0.05 microgram/ml and these values were equivalent or superior to those of the 7 reference drugs.","[Pharmacokinetic, bacteriological and clinical studies of SY5555 in the pediatric field]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7745814/),[μg] / [ml],0.05,114926,DB00535,Cefdinir
,7745814,peak concentrations,"Peak concentrations were detected 1 to 3 hours after administration in all patients and the peak concentrations were 0.93 and 1.21 micrograms/ml at the 5.0 mg/kg dose, 2.85 and 5.49 micrograms/ml at the 10.0 mg/kg dose and 5.79 micrograms/ml at the 15.0 mg/kg dose.","[Pharmacokinetic, bacteriological and clinical studies of SY5555 in the pediatric field]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7745814/),[μg] / [ml],0.93,114927,DB00535,Cefdinir
,7745814,peak concentrations,"Peak concentrations were detected 1 to 3 hours after administration in all patients and the peak concentrations were 0.93 and 1.21 micrograms/ml at the 5.0 mg/kg dose, 2.85 and 5.49 micrograms/ml at the 10.0 mg/kg dose and 5.79 micrograms/ml at the 15.0 mg/kg dose.","[Pharmacokinetic, bacteriological and clinical studies of SY5555 in the pediatric field]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7745814/),[μg] / [ml],1.21,114928,DB00535,Cefdinir
,7745814,peak concentrations,"Peak concentrations were detected 1 to 3 hours after administration in all patients and the peak concentrations were 0.93 and 1.21 micrograms/ml at the 5.0 mg/kg dose, 2.85 and 5.49 micrograms/ml at the 10.0 mg/kg dose and 5.79 micrograms/ml at the 15.0 mg/kg dose.","[Pharmacokinetic, bacteriological and clinical studies of SY5555 in the pediatric field]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7745814/),[μg] / [ml],2.85,114929,DB00535,Cefdinir
,7745814,peak concentrations,"Peak concentrations were detected 1 to 3 hours after administration in all patients and the peak concentrations were 0.93 and 1.21 micrograms/ml at the 5.0 mg/kg dose, 2.85 and 5.49 micrograms/ml at the 10.0 mg/kg dose and 5.79 micrograms/ml at the 15.0 mg/kg dose.","[Pharmacokinetic, bacteriological and clinical studies of SY5555 in the pediatric field]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7745814/),[μg] / [ml],5.49,114930,DB00535,Cefdinir
,7745814,peak concentrations,"Peak concentrations were detected 1 to 3 hours after administration in all patients and the peak concentrations were 0.93 and 1.21 micrograms/ml at the 5.0 mg/kg dose, 2.85 and 5.49 micrograms/ml at the 10.0 mg/kg dose and 5.79 micrograms/ml at the 15.0 mg/kg dose.","[Pharmacokinetic, bacteriological and clinical studies of SY5555 in the pediatric field]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7745814/),[μg] / [ml],5.79,114931,DB00535,Cefdinir
,8222489,area under the concentration curve [AUC(0-12)],"The area under the concentration curve [AUC(0-12)] of cefdinir with concurrent iron was significantly smaller than that with cefdinir alone (mean +/- SD, 0.78 +/- 0.38 versus 10.3 +/- 1.35 micrograms.hr/ml).",Impairment of cefdinir absorption by iron ion. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8222489/),[h·μg] / [ml],0.78,145102,DB00535,Cefdinir
,8222489,area under the concentration curve [AUC(0-12)],"The area under the concentration curve [AUC(0-12)] of cefdinir with concurrent iron was significantly smaller than that with cefdinir alone (mean +/- SD, 0.78 +/- 0.38 versus 10.3 +/- 1.35 micrograms.hr/ml).",Impairment of cefdinir absorption by iron ion. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8222489/),[h·μg] / [ml],10.3,145103,DB00535,Cefdinir
,8222489,AUC(3-12),"While there were no differences in AUC(0-3) between drug alone and drug with iron 3 hours later, the AUC(3-12) with delayed iron was significantly smaller than that of cefdinir alone (4.60 +/- 1.54 versus 8.03 +/- 1.72 micrograms.hr/ml).",Impairment of cefdinir absorption by iron ion. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8222489/),[h·μg] / [ml],4.60,145104,DB00535,Cefdinir
,8222489,AUC(3-12),"While there were no differences in AUC(0-3) between drug alone and drug with iron 3 hours later, the AUC(3-12) with delayed iron was significantly smaller than that of cefdinir alone (4.60 +/- 1.54 versus 8.03 +/- 1.72 micrograms.hr/ml).",Impairment of cefdinir absorption by iron ion. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8222489/),[h·μg] / [ml],8.03,145105,DB00535,Cefdinir
,2283711,peak plasma concentrations,"The peak plasma concentrations were 1.97 micrograms/ml, 0.84 microgram/ml and 1.67 micrograms/ml in the 3 patients.",[Clinical studies on cefdinir in pediatric infections]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2283711/),[μg] / [ml],1.97,150706,DB00535,Cefdinir
,2283711,peak plasma concentrations,"The peak plasma concentrations were 1.97 micrograms/ml, 0.84 microgram/ml and 1.67 micrograms/ml in the 3 patients.",[Clinical studies on cefdinir in pediatric infections]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2283711/),[μg] / [ml],0.84,150707,DB00535,Cefdinir
,2283711,peak plasma concentrations,"The peak plasma concentrations were 1.97 micrograms/ml, 0.84 microgram/ml and 1.67 micrograms/ml in the 3 patients.",[Clinical studies on cefdinir in pediatric infections]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2283711/),[μg] / [ml],1.67,150708,DB00535,Cefdinir
,2283711,urinary excretion rates,"The 0 to 6 or 8-hour urinary excretion rates were 22.2%, 18.1%, and 32.7%, respectively.",[Clinical studies on cefdinir in pediatric infections]. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2283711/),%,22.2,150709,DB00535,Cefdinir
,2283711,urinary excretion rates,"The 0 to 6 or 8-hour urinary excretion rates were 22.2%, 18.1%, and 32.7%, respectively.",[Clinical studies on cefdinir in pediatric infections]. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2283711/),%,18.1,150710,DB00535,Cefdinir
,2283711,urinary excretion rates,"The 0 to 6 or 8-hour urinary excretion rates were 22.2%, 18.1%, and 32.7%, respectively.",[Clinical studies on cefdinir in pediatric infections]. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2283711/),%,32.7,150711,DB00535,Cefdinir
,2283711,overall efficacy rate,"Thus, an overall efficacy rate of 90.5% was achieved.",[Clinical studies on cefdinir in pediatric infections]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2283711/),%,90.5,150712,DB00535,Cefdinir
,2283711,eradication rate,"With regard to microbiological effect on pathogens, 14 of the 15 strains identified as pathogens were eradicated, with an eradication rate of 93.3%.",[Clinical studies on cefdinir in pediatric infections]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2283711/),%,93.3,150713,DB00535,Cefdinir
,7699846,MICs,"MICs of SY5555 against S. aureus, CNS, S. pneumoniae, S. pyogenes, H. influenzae, M. catarrhalis, E. coli and E. cloacae were 0.2, 0.2, 0.2, < or = 0.025, 0.78, 0.2, 0.78 and 3.13 micrograms/ml, respectively, showing excellent antibacterial effects on these pathogens.","[Bacteriological, pharmacokinetic and clinical studies of SY5555 dry syrup in the pediatric field]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7699846/),[μg] / [ml],0.2,151965,DB00535,Cefdinir
,7699846,MICs,"MICs of SY5555 against S. aureus, CNS, S. pneumoniae, S. pyogenes, H. influenzae, M. catarrhalis, E. coli and E. cloacae were 0.2, 0.2, 0.2, < or = 0.025, 0.78, 0.2, 0.78 and 3.13 micrograms/ml, respectively, showing excellent antibacterial effects on these pathogens.","[Bacteriological, pharmacokinetic and clinical studies of SY5555 dry syrup in the pediatric field]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7699846/),[μg] / [ml],<,151966,DB00535,Cefdinir
,7699846,MICs,"MICs of SY5555 against S. aureus, CNS, S. pneumoniae, S. pyogenes, H. influenzae, M. catarrhalis, E. coli and E. cloacae were 0.2, 0.2, 0.2, < or = 0.025, 0.78, 0.2, 0.78 and 3.13 micrograms/ml, respectively, showing excellent antibacterial effects on these pathogens.","[Bacteriological, pharmacokinetic and clinical studies of SY5555 dry syrup in the pediatric field]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7699846/),[μg] / [ml],0.025,151967,DB00535,Cefdinir
,7699846,MICs,"MICs of SY5555 against S. aureus, CNS, S. pneumoniae, S. pyogenes, H. influenzae, M. catarrhalis, E. coli and E. cloacae were 0.2, 0.2, 0.2, < or = 0.025, 0.78, 0.2, 0.78 and 3.13 micrograms/ml, respectively, showing excellent antibacterial effects on these pathogens.","[Bacteriological, pharmacokinetic and clinical studies of SY5555 dry syrup in the pediatric field]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7699846/),[μg] / [ml],0.78,151968,DB00535,Cefdinir
,7699846,MICs,"MICs of SY5555 against S. aureus, CNS, S. pneumoniae, S. pyogenes, H. influenzae, M. catarrhalis, E. coli and E. cloacae were 0.2, 0.2, 0.2, < or = 0.025, 0.78, 0.2, 0.78 and 3.13 micrograms/ml, respectively, showing excellent antibacterial effects on these pathogens.","[Bacteriological, pharmacokinetic and clinical studies of SY5555 dry syrup in the pediatric field]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7699846/),[μg] / [ml],3.13,151969,DB00535,Cefdinir
,7699846,peak plasma concentrations,"With both 5 and 10 mg/kg doses, peak plasma concentrations were reached 1 hour after administration, at 0.25-2.61 micrograms/ml (mean 1.47 micrograms/ml) and 1.08-2.17 micrograms/ml (mean 1.74 micrograms/ml), respectively.","[Bacteriological, pharmacokinetic and clinical studies of SY5555 dry syrup in the pediatric field]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7699846/),[μg] / [ml],0.25-2.61,151970,DB00535,Cefdinir
,7699846,peak plasma concentrations,"With both 5 and 10 mg/kg doses, peak plasma concentrations were reached 1 hour after administration, at 0.25-2.61 micrograms/ml (mean 1.47 micrograms/ml) and 1.08-2.17 micrograms/ml (mean 1.74 micrograms/ml), respectively.","[Bacteriological, pharmacokinetic and clinical studies of SY5555 dry syrup in the pediatric field]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7699846/),[μg] / [ml],1.47,151971,DB00535,Cefdinir
,7699846,peak plasma concentrations,"With both 5 and 10 mg/kg doses, peak plasma concentrations were reached 1 hour after administration, at 0.25-2.61 micrograms/ml (mean 1.47 micrograms/ml) and 1.08-2.17 micrograms/ml (mean 1.74 micrograms/ml), respectively.","[Bacteriological, pharmacokinetic and clinical studies of SY5555 dry syrup in the pediatric field]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7699846/),[μg] / [ml],1.08-2.17,151972,DB00535,Cefdinir
,7699846,peak plasma concentrations,"With both 5 and 10 mg/kg doses, peak plasma concentrations were reached 1 hour after administration, at 0.25-2.61 micrograms/ml (mean 1.47 micrograms/ml) and 1.08-2.17 micrograms/ml (mean 1.74 micrograms/ml), respectively.","[Bacteriological, pharmacokinetic and clinical studies of SY5555 dry syrup in the pediatric field]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7699846/),[μg] / [ml],1.74,151973,DB00535,Cefdinir
,7699846,half-lives,The half-lives 1.12 hours in the 5 mg/kg group and 1.0 hour in the 10 mg/kg group.,"[Bacteriological, pharmacokinetic and clinical studies of SY5555 dry syrup in the pediatric field]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7699846/),h,1.12,151974,DB00535,Cefdinir
,7699846,half-lives,The half-lives 1.12 hours in the 5 mg/kg group and 1.0 hour in the 10 mg/kg group.,"[Bacteriological, pharmacokinetic and clinical studies of SY5555 dry syrup in the pediatric field]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7699846/),h,1.0,151975,DB00535,Cefdinir
,7699846,urinary recovery rates,"The urinary recovery rates were determined in the first 8 hours after administration in the 5 mg/kg and 6 hours in the 10 mg/kg group, and the values were as low as 1.05-12.3% and 1.6-4.33%, respectively.","[Bacteriological, pharmacokinetic and clinical studies of SY5555 dry syrup in the pediatric field]. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7699846/),%,1.05-12.3,151976,DB00535,Cefdinir
,7699846,urinary recovery rates,"The urinary recovery rates were determined in the first 8 hours after administration in the 5 mg/kg and 6 hours in the 10 mg/kg group, and the values were as low as 1.05-12.3% and 1.6-4.33%, respectively.","[Bacteriological, pharmacokinetic and clinical studies of SY5555 dry syrup in the pediatric field]. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7699846/),%,1.6-4.33,151977,DB00535,Cefdinir
,7699846,overall eradication rate,"Eight strains, however, persisted, hence the overall eradication rate was 86.0%.(ABSTRACT TRUNCATED AT 400 WORDS)","[Bacteriological, pharmacokinetic and clinical studies of SY5555 dry syrup in the pediatric field]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7699846/),%,86.0,151978,DB00535,Cefdinir
,2283717,Peak plasma levels,Peak plasma levels of CFDN were 0.85 microgram/ml in one patient and 0.56 microgram/ml in the other.,[Clinical study on cefdinir in pediatric field]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2283717/),[μg] / [ml],0.85,152608,DB00535,Cefdinir
,2283717,Peak plasma levels,Peak plasma levels of CFDN were 0.85 microgram/ml in one patient and 0.56 microgram/ml in the other.,[Clinical study on cefdinir in pediatric field]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2283717/),[μg] / [ml],0.56,152609,DB00535,Cefdinir
,10513846,50% effective doses (ED50),"FK041 exhibited potent therapeutic activity against lethal systemic infections induced by intraperitoneally inoculated Staphylococcus aureus, Escherichia coli, and Klebsiella pneumoniae with 50% effective doses (ED50) in the range of 0.20 to 0.36 mg/kg and was more active than CFDN and CDTR-PI.","In vivo antibacterial activity of FK041, a new orally active cephalosporin. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10513846/),[mg] / [kg],0.20 to 0.36,153730,DB00535,Cefdinir
,3209481,Absolute bioavailabilities,"Absolute bioavailabilities of FK482 were 12.6% in mice, 15.3% in rats, 32.3% in rabbits and 72.3% in dogs.","Pharmacokinetics of FK482, a new orally active cephalosporin, in animals. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3209481/),%,12.6,166314,DB00535,Cefdinir
,3209481,Absolute bioavailabilities,"Absolute bioavailabilities of FK482 were 12.6% in mice, 15.3% in rats, 32.3% in rabbits and 72.3% in dogs.","Pharmacokinetics of FK482, a new orally active cephalosporin, in animals. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3209481/),%,15.3,166315,DB00535,Cefdinir
,3209481,Absolute bioavailabilities,"Absolute bioavailabilities of FK482 were 12.6% in mice, 15.3% in rats, 32.3% in rabbits and 72.3% in dogs.","Pharmacokinetics of FK482, a new orally active cephalosporin, in animals. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3209481/),%,32.3,166316,DB00535,Cefdinir
,3209481,Absolute bioavailabilities,"Absolute bioavailabilities of FK482 were 12.6% in mice, 15.3% in rats, 32.3% in rabbits and 72.3% in dogs.","Pharmacokinetics of FK482, a new orally active cephalosporin, in animals. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3209481/),%,72.3,166317,DB00535,Cefdinir
,3209481,urinary recovery rates,"The urinary recovery rates of FK482 were 9.8% for mice, 15.5% for rats, 45.8% for rabbits and 47.1% for dogs.","Pharmacokinetics of FK482, a new orally active cephalosporin, in animals. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3209481/),%,9.8,166318,DB00535,Cefdinir
,3209481,urinary recovery rates,"The urinary recovery rates of FK482 were 9.8% for mice, 15.5% for rats, 45.8% for rabbits and 47.1% for dogs.","Pharmacokinetics of FK482, a new orally active cephalosporin, in animals. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3209481/),%,15.5,166319,DB00535,Cefdinir
,3209481,urinary recovery rates,"The urinary recovery rates of FK482 were 9.8% for mice, 15.5% for rats, 45.8% for rabbits and 47.1% for dogs.","Pharmacokinetics of FK482, a new orally active cephalosporin, in animals. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3209481/),%,45.8,166320,DB00535,Cefdinir
,3209481,urinary recovery rates,"The urinary recovery rates of FK482 were 9.8% for mice, 15.5% for rats, 45.8% for rabbits and 47.1% for dogs.","Pharmacokinetics of FK482, a new orally active cephalosporin, in animals. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3209481/),%,47.1,166321,DB00535,Cefdinir
,3209481,biliary recovery rate,The biliary recovery rate of FK482 was low; 1.4% in rats and less than 0.1% in rabbits and dogs.,"Pharmacokinetics of FK482, a new orally active cephalosporin, in animals. ","t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3209481/),%,1.4,166322,DB00535,Cefdinir
less,3209481,biliary recovery rate,The biliary recovery rate of FK482 was low; 1.4% in rats and less than 0.1% in rabbits and dogs.,"Pharmacokinetics of FK482, a new orally active cephalosporin, in animals. ","t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3209481/),%,0.1,166323,DB00535,Cefdinir
,3209481,serum-protein binding,"The serum-protein binding of FK482 was almost the same as that of cefixime: 60-77% for mouse, rabbit and human serum, and 90-93% for rat and dog serum.","Pharmacokinetics of FK482, a new orally active cephalosporin, in animals. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3209481/),%,60-77,166324,DB00535,Cefdinir
,3209481,serum-protein binding,"The serum-protein binding of FK482 was almost the same as that of cefixime: 60-77% for mouse, rabbit and human serum, and 90-93% for rat and dog serum.","Pharmacokinetics of FK482, a new orally active cephalosporin, in animals. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3209481/),%,90-93,166325,DB00535,Cefdinir
,2086818,serum half-life,The serum half-life of the drug was 2.45 hours.,[Clinical investigation of cefdinir in the pediatric field]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2086818/),h,2.45,191317,DB00535,Cefdinir
,2086818,eradication rate,"3. As for bacteriological effects on 20 strains of causative organisms, all the 10 strains of Gram-positive organisms were eradicated, with an eradication rate of 100%.",[Clinical investigation of cefdinir in the pediatric field]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2086818/),%,100,191318,DB00535,Cefdinir
,2086818,eradication rate,"Meanwhile, the eradication rate on 10 strains of Gram-negative organisms was 87.5%.",[Clinical investigation of cefdinir in the pediatric field]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2086818/),%,87.5,191319,DB00535,Cefdinir
,2086818,eradication rate,"Overall, bacteriological effect was ""eradicated"" in 17 strains, ""decreased"" in one, and ""unknown"" in 2, with an eradication rate of 94.4%.",[Clinical investigation of cefdinir in the pediatric field]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2086818/),%,94.4,191320,DB00535,Cefdinir
,1762172,Cmax,"Cmax and T 1/2 were 0.92 +/- 0.45 micrograms/ml and 1.95 +/- 1.06 hours, respectively, in the fasting state, and were 0.63 +/- 0.29 micrograms/ml and 2.26 +/- 0.65 hours, respectively, in the non-fasting state, at a dose level of 3 mg (potency)/kg.",[Pharmacokinetic and clinical studies of cefdinir in the pediatric field. Pediatric Study Group of Cefdinir]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1762172/),[μg] / [ml],0.92,200898,DB00535,Cefdinir
,1762172,Cmax,"Cmax and T 1/2 were 0.92 +/- 0.45 micrograms/ml and 1.95 +/- 1.06 hours, respectively, in the fasting state, and were 0.63 +/- 0.29 micrograms/ml and 2.26 +/- 0.65 hours, respectively, in the non-fasting state, at a dose level of 3 mg (potency)/kg.",[Pharmacokinetic and clinical studies of cefdinir in the pediatric field. Pediatric Study Group of Cefdinir]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1762172/),[μg] / [ml],0.63,200899,DB00535,Cefdinir
,1762172,T 1/2,"Cmax and T 1/2 were 0.92 +/- 0.45 micrograms/ml and 1.95 +/- 1.06 hours, respectively, in the fasting state, and were 0.63 +/- 0.29 micrograms/ml and 2.26 +/- 0.65 hours, respectively, in the non-fasting state, at a dose level of 3 mg (potency)/kg.",[Pharmacokinetic and clinical studies of cefdinir in the pediatric field. Pediatric Study Group of Cefdinir]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1762172/),h,1.95,200900,DB00535,Cefdinir
,1762172,T 1/2,"Cmax and T 1/2 were 0.92 +/- 0.45 micrograms/ml and 1.95 +/- 1.06 hours, respectively, in the fasting state, and were 0.63 +/- 0.29 micrograms/ml and 2.26 +/- 0.65 hours, respectively, in the non-fasting state, at a dose level of 3 mg (potency)/kg.",[Pharmacokinetic and clinical studies of cefdinir in the pediatric field. Pediatric Study Group of Cefdinir]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1762172/),h,2.26,200901,DB00535,Cefdinir
,1762172,Cmax,"At a dose level of 6 mg (potency)/kg, Cmax and T 1/2 were 1.29 +/- 0.49 micrograms/ml and 2.11 +/- 1.85 hours, respectively, in the fasting state and were 1.28 +/- 0.48 micrograms/ml and 2.01 +/- 0.84 hours, respectively, in the non-fasting state.",[Pharmacokinetic and clinical studies of cefdinir in the pediatric field. Pediatric Study Group of Cefdinir]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1762172/),[μg] / [ml],1.29,200902,DB00535,Cefdinir
,1762172,Cmax,"At a dose level of 6 mg (potency)/kg, Cmax and T 1/2 were 1.29 +/- 0.49 micrograms/ml and 2.11 +/- 1.85 hours, respectively, in the fasting state and were 1.28 +/- 0.48 micrograms/ml and 2.01 +/- 0.84 hours, respectively, in the non-fasting state.",[Pharmacokinetic and clinical studies of cefdinir in the pediatric field. Pediatric Study Group of Cefdinir]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1762172/),[μg] / [ml],1.28,200903,DB00535,Cefdinir
,1762172,T 1/2,"At a dose level of 6 mg (potency)/kg, Cmax and T 1/2 were 1.29 +/- 0.49 micrograms/ml and 2.11 +/- 1.85 hours, respectively, in the fasting state and were 1.28 +/- 0.48 micrograms/ml and 2.01 +/- 0.84 hours, respectively, in the non-fasting state.",[Pharmacokinetic and clinical studies of cefdinir in the pediatric field. Pediatric Study Group of Cefdinir]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1762172/),h,2.11,200904,DB00535,Cefdinir
,1762172,T 1/2,"At a dose level of 6 mg (potency)/kg, Cmax and T 1/2 were 1.29 +/- 0.49 micrograms/ml and 2.11 +/- 1.85 hours, respectively, in the fasting state and were 1.28 +/- 0.48 micrograms/ml and 2.01 +/- 0.84 hours, respectively, in the non-fasting state.",[Pharmacokinetic and clinical studies of cefdinir in the pediatric field. Pediatric Study Group of Cefdinir]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1762172/),h,2.01,200905,DB00535,Cefdinir
,1762172,Urinary recovery rates,"Urinary recovery rates in the first 8 hours were 20.5 +/- 8.8% in the fasting state and 14.8 +/- 5.9% in the non-fasting at a dose level of 3 mg (potency)/kg and 16.5 +/- 6.7% and 17.8 +/- 2.4%, respectively, at 6 mg (potency)/kg. 2.",[Pharmacokinetic and clinical studies of cefdinir in the pediatric field. Pediatric Study Group of Cefdinir]. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1762172/),%,20.5,200906,DB00535,Cefdinir
,1762172,Urinary recovery rates,"Urinary recovery rates in the first 8 hours were 20.5 +/- 8.8% in the fasting state and 14.8 +/- 5.9% in the non-fasting at a dose level of 3 mg (potency)/kg and 16.5 +/- 6.7% and 17.8 +/- 2.4%, respectively, at 6 mg (potency)/kg. 2.",[Pharmacokinetic and clinical studies of cefdinir in the pediatric field. Pediatric Study Group of Cefdinir]. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1762172/),%,14.8,200907,DB00535,Cefdinir
,1762172,Urinary recovery rates,"Urinary recovery rates in the first 8 hours were 20.5 +/- 8.8% in the fasting state and 14.8 +/- 5.9% in the non-fasting at a dose level of 3 mg (potency)/kg and 16.5 +/- 6.7% and 17.8 +/- 2.4%, respectively, at 6 mg (potency)/kg. 2.",[Pharmacokinetic and clinical studies of cefdinir in the pediatric field. Pediatric Study Group of Cefdinir]. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1762172/),%,16.5,200908,DB00535,Cefdinir
,1762172,Urinary recovery rates,"Urinary recovery rates in the first 8 hours were 20.5 +/- 8.8% in the fasting state and 14.8 +/- 5.9% in the non-fasting at a dose level of 3 mg (potency)/kg and 16.5 +/- 6.7% and 17.8 +/- 2.4%, respectively, at 6 mg (potency)/kg. 2.",[Pharmacokinetic and clinical studies of cefdinir in the pediatric field. Pediatric Study Group of Cefdinir]. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1762172/),%,17.8,200909,DB00535,Cefdinir
,1762172,Bacteriological eradication rate,"Bacteriological eradication rate was 82.1% for 491 strains in the 5% granule group, and was 84.0% for 175 strains in the 10% granule group.",[Pharmacokinetic and clinical studies of cefdinir in the pediatric field. Pediatric Study Group of Cefdinir]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1762172/),%,82.1,200910,DB00535,Cefdinir
,1762172,Bacteriological eradication rate,"Bacteriological eradication rate was 82.1% for 491 strains in the 5% granule group, and was 84.0% for 175 strains in the 10% granule group.",[Pharmacokinetic and clinical studies of cefdinir in the pediatric field. Pediatric Study Group of Cefdinir]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1762172/),%,84.0,200911,DB00535,Cefdinir
,1762168,half-life,Average plasma concentrations in a group of patients administered with 5% fine granules peaked at 3 hours after administration with a level of 1.05 +/- 0.29 micrograms/ml (mean +/- S.E.) and decreased to 0.12 +/- 0.05 micrograms/ml at 8 hours with a half-life of 1.48 +/- 0.09 hours.,"[Pharmacokinetic, bacteriological and clinical evaluations of cefdinir 10% fine granules in pediatrics]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1762168/),h,1.48,210220,DB00535,Cefdinir
,1762168,half-life,"In the group administered with 10% fine granules, average plasma concentrations peaked at 2 hours after administration with a level of 1.32 +/- 0.12 micrograms/ml, and decreased to 0.20 +/- 0.11 microgram/ml at 8 hours with a half-life of 1.68 +/- 0.28 hours.","[Pharmacokinetic, bacteriological and clinical evaluations of cefdinir 10% fine granules in pediatrics]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1762168/),h,1.68,210221,DB00535,Cefdinir
,1762168,urinary recovery rates,"The first 8-hour urinary recovery rates of CFDN in the 5% and 10% fine granules groups averaged 19.64 +/- 5.69% and 23.37 +/- 2.36%, respectively.","[Pharmacokinetic, bacteriological and clinical evaluations of cefdinir 10% fine granules in pediatrics]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1762168/),%,19.64,210222,DB00535,Cefdinir
,1762168,urinary recovery rates,"The first 8-hour urinary recovery rates of CFDN in the 5% and 10% fine granules groups averaged 19.64 +/- 5.69% and 23.37 +/- 2.36%, respectively.","[Pharmacokinetic, bacteriological and clinical evaluations of cefdinir 10% fine granules in pediatrics]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1762168/),%,23.37,210223,DB00535,Cefdinir
,1762168,overall efficacy rate,The overall efficacy rate was 100%.,"[Pharmacokinetic, bacteriological and clinical evaluations of cefdinir 10% fine granules in pediatrics]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1762168/),%,100,210224,DB00535,Cefdinir
,1762168,overall eradication rate,The overall eradication rate was 90.0%.,"[Pharmacokinetic, bacteriological and clinical evaluations of cefdinir 10% fine granules in pediatrics]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1762168/),%,90.0,210225,DB00535,Cefdinir
,2283715,eradication rate,"4. Bacteria identified from various diseases were 29 strains of 9 species, and the eradication rate was 82.8%.",[Clinical studies on cefdinir granules in pediatric field]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2283715/),%,82.8,220130,DB00535,Cefdinir
,15631795,MIC90,The value of MIC90 s cefdinir against these bacterial strains except penicillin non-sensitive pneumococci were 0.031-1 mg/L.,"[Comparison of pharmacokinetics/pharmacodynamics of cefdinir, cefpodoxime proxetil and cefaclor against common bacteria of community acquired infections]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15631795/),[mg] / [l],0.031-1,240503,DB00535,Cefdinir
,15631795,quickly reached peak concentration,"After oral administration of 250 mg cefaclor, the drug concentration quickly reached peak concentration of 4.95 mg/L +/- 2.41 mg/L and the eliminative half time was 0.69 h +/- 0.6 h; the Tmax, Cmax and T1/2beta of cefdinir and cefpodoxime after oral administration of 100 mg were 2.5 h +/- 0.48 h, 0.81 mg/L +/- 0.19 mg/L, 1.73 h +/- 0.3 h and 2.38 h +/- 0.43 h, 1.12 mg/L +/- 0.28 mg/L, 1.92 h +/- 0.55 h, respectively.","[Comparison of pharmacokinetics/pharmacodynamics of cefdinir, cefpodoxime proxetil and cefaclor against common bacteria of community acquired infections]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15631795/),[mg] / [l],4.95,240504,DB00535,Cefdinir
,15631795,eliminative half time,"After oral administration of 250 mg cefaclor, the drug concentration quickly reached peak concentration of 4.95 mg/L +/- 2.41 mg/L and the eliminative half time was 0.69 h +/- 0.6 h; the Tmax, Cmax and T1/2beta of cefdinir and cefpodoxime after oral administration of 100 mg were 2.5 h +/- 0.48 h, 0.81 mg/L +/- 0.19 mg/L, 1.73 h +/- 0.3 h and 2.38 h +/- 0.43 h, 1.12 mg/L +/- 0.28 mg/L, 1.92 h +/- 0.55 h, respectively.","[Comparison of pharmacokinetics/pharmacodynamics of cefdinir, cefpodoxime proxetil and cefaclor against common bacteria of community acquired infections]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15631795/),h,0.69,240505,DB00535,Cefdinir
,15631795,Tmax,"After oral administration of 250 mg cefaclor, the drug concentration quickly reached peak concentration of 4.95 mg/L +/- 2.41 mg/L and the eliminative half time was 0.69 h +/- 0.6 h; the Tmax, Cmax and T1/2beta of cefdinir and cefpodoxime after oral administration of 100 mg were 2.5 h +/- 0.48 h, 0.81 mg/L +/- 0.19 mg/L, 1.73 h +/- 0.3 h and 2.38 h +/- 0.43 h, 1.12 mg/L +/- 0.28 mg/L, 1.92 h +/- 0.55 h, respectively.","[Comparison of pharmacokinetics/pharmacodynamics of cefdinir, cefpodoxime proxetil and cefaclor against common bacteria of community acquired infections]. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15631795/),h,2.5,240506,DB00535,Cefdinir
,15631795,Cmax,"After oral administration of 250 mg cefaclor, the drug concentration quickly reached peak concentration of 4.95 mg/L +/- 2.41 mg/L and the eliminative half time was 0.69 h +/- 0.6 h; the Tmax, Cmax and T1/2beta of cefdinir and cefpodoxime after oral administration of 100 mg were 2.5 h +/- 0.48 h, 0.81 mg/L +/- 0.19 mg/L, 1.73 h +/- 0.3 h and 2.38 h +/- 0.43 h, 1.12 mg/L +/- 0.28 mg/L, 1.92 h +/- 0.55 h, respectively.","[Comparison of pharmacokinetics/pharmacodynamics of cefdinir, cefpodoxime proxetil and cefaclor against common bacteria of community acquired infections]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15631795/),[mg] / [l],0.81,240507,DB00535,Cefdinir
,15631795,Cmax,"After oral administration of 250 mg cefaclor, the drug concentration quickly reached peak concentration of 4.95 mg/L +/- 2.41 mg/L and the eliminative half time was 0.69 h +/- 0.6 h; the Tmax, Cmax and T1/2beta of cefdinir and cefpodoxime after oral administration of 100 mg were 2.5 h +/- 0.48 h, 0.81 mg/L +/- 0.19 mg/L, 1.73 h +/- 0.3 h and 2.38 h +/- 0.43 h, 1.12 mg/L +/- 0.28 mg/L, 1.92 h +/- 0.55 h, respectively.","[Comparison of pharmacokinetics/pharmacodynamics of cefdinir, cefpodoxime proxetil and cefaclor against common bacteria of community acquired infections]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15631795/),h,1.73,240508,DB00535,Cefdinir
,15631795,T1/2beta,"After oral administration of 250 mg cefaclor, the drug concentration quickly reached peak concentration of 4.95 mg/L +/- 2.41 mg/L and the eliminative half time was 0.69 h +/- 0.6 h; the Tmax, Cmax and T1/2beta of cefdinir and cefpodoxime after oral administration of 100 mg were 2.5 h +/- 0.48 h, 0.81 mg/L +/- 0.19 mg/L, 1.73 h +/- 0.3 h and 2.38 h +/- 0.43 h, 1.12 mg/L +/- 0.28 mg/L, 1.92 h +/- 0.55 h, respectively.","[Comparison of pharmacokinetics/pharmacodynamics of cefdinir, cefpodoxime proxetil and cefaclor against common bacteria of community acquired infections]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15631795/),h,2.38,240509,DB00535,Cefdinir
<,10587878,MIC,"In vitro activities (MICs) of CPDX, CFDN, CDTR, and FRPM against clinical isolates, penicillin-susceptible S. pneumoniae (PSSP: MIC of penicillin G, < or = 0.063 microgram/ml), penicillin-intermediate S. pneumoniae (PISP: MIC of penicillin G, 0.125-1 microgram/ml), and penicillin-resistant S. pneumoniae (PRSP: MIC of penicillin G, > or = 2 micrograms/ml), were tested by an agar dilution method.",[In vitro and in vivo activities of cefpodoxime proxetil against penicillin-resistant Streptococcus pneumoniae]. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10587878/),[μg] / [ml],0.063,250165,DB00535,Cefdinir
,10587878,MIC,"In vitro activities (MICs) of CPDX, CFDN, CDTR, and FRPM against clinical isolates, penicillin-susceptible S. pneumoniae (PSSP: MIC of penicillin G, < or = 0.063 microgram/ml), penicillin-intermediate S. pneumoniae (PISP: MIC of penicillin G, 0.125-1 microgram/ml), and penicillin-resistant S. pneumoniae (PRSP: MIC of penicillin G, > or = 2 micrograms/ml), were tested by an agar dilution method.",[In vitro and in vivo activities of cefpodoxime proxetil against penicillin-resistant Streptococcus pneumoniae]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10587878/),[μg] / [ml],0.125-1,250166,DB00535,Cefdinir
>,10587878,MIC,"In vitro activities (MICs) of CPDX, CFDN, CDTR, and FRPM against clinical isolates, penicillin-susceptible S. pneumoniae (PSSP: MIC of penicillin G, < or = 0.063 microgram/ml), penicillin-intermediate S. pneumoniae (PISP: MIC of penicillin G, 0.125-1 microgram/ml), and penicillin-resistant S. pneumoniae (PRSP: MIC of penicillin G, > or = 2 micrograms/ml), were tested by an agar dilution method.",[In vitro and in vivo activities of cefpodoxime proxetil against penicillin-resistant Streptococcus pneumoniae]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10587878/),[μg] / [ml],2,250167,DB00535,Cefdinir
,10587878,MIC80s,"The MIC80s of CPDX against 27 PSSP strains, 23 PISP strains, and 23 PRSP strains were 0.032, 1, and 8 micrograms/ml, respectively, which were superior to or equal to those of CFDN (0.063, 4, and 8 micrograms/ml) and were inferior to those of CDTR (0.016, 0.5, and 1 microgram/ml) and FRPM (< or = 0.008, 0.25, and 1 microgram/ml).",[In vitro and in vivo activities of cefpodoxime proxetil against penicillin-resistant Streptococcus pneumoniae]. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10587878/),[μg] / [ml],0.032,250168,DB00535,Cefdinir
,10587878,MIC80s,"The MIC80s of CPDX against 27 PSSP strains, 23 PISP strains, and 23 PRSP strains were 0.032, 1, and 8 micrograms/ml, respectively, which were superior to or equal to those of CFDN (0.063, 4, and 8 micrograms/ml) and were inferior to those of CDTR (0.016, 0.5, and 1 microgram/ml) and FRPM (< or = 0.008, 0.25, and 1 microgram/ml).",[In vitro and in vivo activities of cefpodoxime proxetil against penicillin-resistant Streptococcus pneumoniae]. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10587878/),[μg] / [ml],1,250169,DB00535,Cefdinir
,10587878,MIC80s,"The MIC80s of CPDX against 27 PSSP strains, 23 PISP strains, and 23 PRSP strains were 0.032, 1, and 8 micrograms/ml, respectively, which were superior to or equal to those of CFDN (0.063, 4, and 8 micrograms/ml) and were inferior to those of CDTR (0.016, 0.5, and 1 microgram/ml) and FRPM (< or = 0.008, 0.25, and 1 microgram/ml).",[In vitro and in vivo activities of cefpodoxime proxetil against penicillin-resistant Streptococcus pneumoniae]. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10587878/),[μg] / [ml],8,250170,DB00535,Cefdinir
,10587878,MIC80s,"The MIC80s of CPDX against 27 PSSP strains, 23 PISP strains, and 23 PRSP strains were 0.032, 1, and 8 micrograms/ml, respectively, which were superior to or equal to those of CFDN (0.063, 4, and 8 micrograms/ml) and were inferior to those of CDTR (0.016, 0.5, and 1 microgram/ml) and FRPM (< or = 0.008, 0.25, and 1 microgram/ml).",[In vitro and in vivo activities of cefpodoxime proxetil against penicillin-resistant Streptococcus pneumoniae]. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10587878/),[μg] / [ml],0.063,250171,DB00535,Cefdinir
,10587878,MIC80s,"The MIC80s of CPDX against 27 PSSP strains, 23 PISP strains, and 23 PRSP strains were 0.032, 1, and 8 micrograms/ml, respectively, which were superior to or equal to those of CFDN (0.063, 4, and 8 micrograms/ml) and were inferior to those of CDTR (0.016, 0.5, and 1 microgram/ml) and FRPM (< or = 0.008, 0.25, and 1 microgram/ml).",[In vitro and in vivo activities of cefpodoxime proxetil against penicillin-resistant Streptococcus pneumoniae]. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10587878/),[μg] / [ml],4,250172,DB00535,Cefdinir
,10587878,MIC80s,"The MIC80s of CPDX against 27 PSSP strains, 23 PISP strains, and 23 PRSP strains were 0.032, 1, and 8 micrograms/ml, respectively, which were superior to or equal to those of CFDN (0.063, 4, and 8 micrograms/ml) and were inferior to those of CDTR (0.016, 0.5, and 1 microgram/ml) and FRPM (< or = 0.008, 0.25, and 1 microgram/ml).",[In vitro and in vivo activities of cefpodoxime proxetil against penicillin-resistant Streptococcus pneumoniae]. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10587878/),[μg] / [ml],0.016,250173,DB00535,Cefdinir
,10587878,MIC80s,"The MIC80s of CPDX against 27 PSSP strains, 23 PISP strains, and 23 PRSP strains were 0.032, 1, and 8 micrograms/ml, respectively, which were superior to or equal to those of CFDN (0.063, 4, and 8 micrograms/ml) and were inferior to those of CDTR (0.016, 0.5, and 1 microgram/ml) and FRPM (< or = 0.008, 0.25, and 1 microgram/ml).",[In vitro and in vivo activities of cefpodoxime proxetil against penicillin-resistant Streptococcus pneumoniae]. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10587878/),[μg] / [ml],0.5,250174,DB00535,Cefdinir
,10587878,MIC80s,"The MIC80s of CPDX against 27 PSSP strains, 23 PISP strains, and 23 PRSP strains were 0.032, 1, and 8 micrograms/ml, respectively, which were superior to or equal to those of CFDN (0.063, 4, and 8 micrograms/ml) and were inferior to those of CDTR (0.016, 0.5, and 1 microgram/ml) and FRPM (< or = 0.008, 0.25, and 1 microgram/ml).",[In vitro and in vivo activities of cefpodoxime proxetil against penicillin-resistant Streptococcus pneumoniae]. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10587878/),[μg] / [ml],1,250175,DB00535,Cefdinir
,10587878,MIC80s,"The MIC80s of CPDX against 27 PSSP strains, 23 PISP strains, and 23 PRSP strains were 0.032, 1, and 8 micrograms/ml, respectively, which were superior to or equal to those of CFDN (0.063, 4, and 8 micrograms/ml) and were inferior to those of CDTR (0.016, 0.5, and 1 microgram/ml) and FRPM (< or = 0.008, 0.25, and 1 microgram/ml).",[In vitro and in vivo activities of cefpodoxime proxetil against penicillin-resistant Streptococcus pneumoniae]. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10587878/),[μg] / [ml],0.,250176,DB00535,Cefdinir
,10587878,MIC80s,"The MIC80s of CPDX against 27 PSSP strains, 23 PISP strains, and 23 PRSP strains were 0.032, 1, and 8 micrograms/ml, respectively, which were superior to or equal to those of CFDN (0.063, 4, and 8 micrograms/ml) and were inferior to those of CDTR (0.016, 0.5, and 1 microgram/ml) and FRPM (< or = 0.008, 0.25, and 1 microgram/ml).",[In vitro and in vivo activities of cefpodoxime proxetil against penicillin-resistant Streptococcus pneumoniae]. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10587878/),[μg] / [ml],0.25,250177,DB00535,Cefdinir
,10587878,MICs,"MICs of the drugs against PRSP 9605, 9601, and 10692 were as follows: CPDX, 4, 4 and 2 micrograms/ml; CFDN, 16, 16, and 4 micrograms/ml; CDTR, 1, 1, and 0.5 microgram/ml; and FRPM, 1, 0.5, and 0.5 microgram/ml, respectively.",[In vitro and in vivo activities of cefpodoxime proxetil against penicillin-resistant Streptococcus pneumoniae]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10587878/),[μg] / [ml],4,250178,DB00535,Cefdinir
,10587878,MICs,"MICs of the drugs against PRSP 9605, 9601, and 10692 were as follows: CPDX, 4, 4 and 2 micrograms/ml; CFDN, 16, 16, and 4 micrograms/ml; CDTR, 1, 1, and 0.5 microgram/ml; and FRPM, 1, 0.5, and 0.5 microgram/ml, respectively.",[In vitro and in vivo activities of cefpodoxime proxetil against penicillin-resistant Streptococcus pneumoniae]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10587878/),[μg] / [ml],2,250179,DB00535,Cefdinir
,10587878,MICs,"MICs of the drugs against PRSP 9605, 9601, and 10692 were as follows: CPDX, 4, 4 and 2 micrograms/ml; CFDN, 16, 16, and 4 micrograms/ml; CDTR, 1, 1, and 0.5 microgram/ml; and FRPM, 1, 0.5, and 0.5 microgram/ml, respectively.",[In vitro and in vivo activities of cefpodoxime proxetil against penicillin-resistant Streptococcus pneumoniae]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10587878/),[μg] / [ml],16,250180,DB00535,Cefdinir
,10587878,MICs,"MICs of the drugs against PRSP 9605, 9601, and 10692 were as follows: CPDX, 4, 4 and 2 micrograms/ml; CFDN, 16, 16, and 4 micrograms/ml; CDTR, 1, 1, and 0.5 microgram/ml; and FRPM, 1, 0.5, and 0.5 microgram/ml, respectively.",[In vitro and in vivo activities of cefpodoxime proxetil against penicillin-resistant Streptococcus pneumoniae]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10587878/),[μg] / [ml],1,250181,DB00535,Cefdinir
,10587878,MICs,"MICs of the drugs against PRSP 9605, 9601, and 10692 were as follows: CPDX, 4, 4 and 2 micrograms/ml; CFDN, 16, 16, and 4 micrograms/ml; CDTR, 1, 1, and 0.5 microgram/ml; and FRPM, 1, 0.5, and 0.5 microgram/ml, respectively.",[In vitro and in vivo activities of cefpodoxime proxetil against penicillin-resistant Streptococcus pneumoniae]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10587878/),[μg] / [ml],0.5,250182,DB00535,Cefdinir
less,16531128,run time,The chromatographic run time for each plasma sample was less than 3 min.,Selective method for the determination of cefdinir in human plasma using liquid chromatography electrospray ionization tandam mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16531128/),min,3,258053,DB00535,Cefdinir
,26548349,bioavailability,Cefdinir (Cef) is an orally active Biopharmaceutics Classification System (BCS) class IV drug with incomplete absorption and low bioavailability (16-21%).,"Cefdinir nanosuspension for improved oral bioavailability by media milling technique: formulation, characterization and in vitro-in vivo evaluations. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26548349/),%,16-21,258825,DB00535,Cefdinir
,26548349,zeta potential,"The particle size and zeta potential were found to be 224.2 ± 2.7 nm and -15.7 ± 1.9 mV, respectively.","Cefdinir nanosuspension for improved oral bioavailability by media milling technique: formulation, characterization and in vitro-in vivo evaluations. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26548349/),mv,-,258826,DB00535,Cefdinir
,26548349,zeta potential,"The particle size and zeta potential were found to be 224.2 ± 2.7 nm and -15.7 ± 1.9 mV, respectively.","Cefdinir nanosuspension for improved oral bioavailability by media milling technique: formulation, characterization and in vitro-in vivo evaluations. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26548349/),mv,15.7,258827,DB00535,Cefdinir
,26548349,Saturation solubility,Saturation solubility of NS was found to be 1985.3 ± 10.2 µg/ml which was 5.64 times higher than pure drug (352.2 ± 6.5 µg/ml).,"Cefdinir nanosuspension for improved oral bioavailability by media milling technique: formulation, characterization and in vitro-in vivo evaluations. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26548349/),[μg] / [ml],1985.3,258828,DB00535,Cefdinir
,26548349,Saturation solubility,Saturation solubility of NS was found to be 1985.3 ± 10.2 µg/ml which was 5.64 times higher than pure drug (352.2 ± 6.5 µg/ml).,"Cefdinir nanosuspension for improved oral bioavailability by media milling technique: formulation, characterization and in vitro-in vivo evaluations. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26548349/),[μg] / [ml],352.2,258829,DB00535,Cefdinir
,26548349,drug release,"Results of in vitro release studies and ex vivo permeation studies showed improved drug release of 88.2 1 ± 2.90 and 83.11 ± 2.14%, respectively, from NS after 24 h as compared to drug release of 54.09 ± 2.54 and 48.2 1 ± 1.27%, respectively, from the marketed suspension (Adcef).","Cefdinir nanosuspension for improved oral bioavailability by media milling technique: formulation, characterization and in vitro-in vivo evaluations. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26548349/),%,88.2,258830,DB00535,Cefdinir
,26548349,drug release,"Results of in vitro release studies and ex vivo permeation studies showed improved drug release of 88.2 1 ± 2.90 and 83.11 ± 2.14%, respectively, from NS after 24 h as compared to drug release of 54.09 ± 2.54 and 48.2 1 ± 1.27%, respectively, from the marketed suspension (Adcef).","Cefdinir nanosuspension for improved oral bioavailability by media milling technique: formulation, characterization and in vitro-in vivo evaluations. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26548349/),%,83.11,258831,DB00535,Cefdinir
,26548349,drug release,"Results of in vitro release studies and ex vivo permeation studies showed improved drug release of 88.2 1 ± 2.90 and 83.11 ± 2.14%, respectively, from NS after 24 h as compared to drug release of 54.09 ± 2.54 and 48.2 1 ± 1.27%, respectively, from the marketed suspension (Adcef).","Cefdinir nanosuspension for improved oral bioavailability by media milling technique: formulation, characterization and in vitro-in vivo evaluations. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26548349/),%,54.09,258832,DB00535,Cefdinir
,26548349,drug release,"Results of in vitro release studies and ex vivo permeation studies showed improved drug release of 88.2 1 ± 2.90 and 83.11 ± 2.14%, respectively, from NS after 24 h as compared to drug release of 54.09 ± 2.54 and 48.2 1 ± 1.27%, respectively, from the marketed suspension (Adcef).","Cefdinir nanosuspension for improved oral bioavailability by media milling technique: formulation, characterization and in vitro-in vivo evaluations. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26548349/),%,48.2,258833,DB00535,Cefdinir
,1495196,MIC80's,"MIC80's of CFDN against S. aureus, S. pneumoniae, S. pyogenes, H. influenzae, B. catarrhalis, K. pneumoniae and E. coli were 0.78, 0.20, less than or equal to 0.025, 0.39, 0.10, 0.20 and 0.10 micrograms/ml, respectively.","[Bacteriological, pharmacokinetic and clinical studies of 5% and 10% granules of cefdinir in the pediatric field]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1495196/),[μg] / [ml],0.78,263805,DB00535,Cefdinir
,1495196,MIC80's,"MIC80's of CFDN against S. aureus, S. pneumoniae, S. pyogenes, H. influenzae, B. catarrhalis, K. pneumoniae and E. coli were 0.78, 0.20, less than or equal to 0.025, 0.39, 0.10, 0.20 and 0.10 micrograms/ml, respectively.","[Bacteriological, pharmacokinetic and clinical studies of 5% and 10% granules of cefdinir in the pediatric field]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1495196/),[μg] / [ml],0.20,263806,DB00535,Cefdinir
,1495196,MIC80's,"MIC80's of CFDN against S. aureus, S. pneumoniae, S. pyogenes, H. influenzae, B. catarrhalis, K. pneumoniae and E. coli were 0.78, 0.20, less than or equal to 0.025, 0.39, 0.10, 0.20 and 0.10 micrograms/ml, respectively.","[Bacteriological, pharmacokinetic and clinical studies of 5% and 10% granules of cefdinir in the pediatric field]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1495196/),[μg] / [ml],less,263807,DB00535,Cefdinir
,1495196,MIC80's,"MIC80's of CFDN against S. aureus, S. pneumoniae, S. pyogenes, H. influenzae, B. catarrhalis, K. pneumoniae and E. coli were 0.78, 0.20, less than or equal to 0.025, 0.39, 0.10, 0.20 and 0.10 micrograms/ml, respectively.","[Bacteriological, pharmacokinetic and clinical studies of 5% and 10% granules of cefdinir in the pediatric field]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1495196/),[μg] / [ml],0.025,263808,DB00535,Cefdinir
,1495196,MIC80's,"MIC80's of CFDN against S. aureus, S. pneumoniae, S. pyogenes, H. influenzae, B. catarrhalis, K. pneumoniae and E. coli were 0.78, 0.20, less than or equal to 0.025, 0.39, 0.10, 0.20 and 0.10 micrograms/ml, respectively.","[Bacteriological, pharmacokinetic and clinical studies of 5% and 10% granules of cefdinir in the pediatric field]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1495196/),[μg] / [ml],0.39,263809,DB00535,Cefdinir
,1495196,MIC80's,"MIC80's of CFDN against S. aureus, S. pneumoniae, S. pyogenes, H. influenzae, B. catarrhalis, K. pneumoniae and E. coli were 0.78, 0.20, less than or equal to 0.025, 0.39, 0.10, 0.20 and 0.10 micrograms/ml, respectively.","[Bacteriological, pharmacokinetic and clinical studies of 5% and 10% granules of cefdinir in the pediatric field]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1495196/),[μg] / [ml],0.10,263810,DB00535,Cefdinir
,1495196,MIC80,"As for antibacterial activities against Gram-negative bacteria (GNB), the MIC80 of CFIX against H. influenzae was 0.05 micrograms/ml, which was slightly lower than that of CFDN.","[Bacteriological, pharmacokinetic and clinical studies of 5% and 10% granules of cefdinir in the pediatric field]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1495196/),[μg] / [ml],0.05,263811,DB00535,Cefdinir
,1495196,peak blood concentrations (Cmax's),"At a dose of 3 mg/kg, peak blood concentrations (Cmax's) of CFDN ranged from 0.20 to 2.12 micrograms/ml with 5% granules and from 0.50 to 1.15 micrograms/ml with 10% granules at 2 to 3 hours after dosing.","[Bacteriological, pharmacokinetic and clinical studies of 5% and 10% granules of cefdinir in the pediatric field]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1495196/),[μg] / [ml],0.20 to 2.12,263812,DB00535,Cefdinir
,1495196,peak blood concentrations (Cmax's),"At a dose of 3 mg/kg, peak blood concentrations (Cmax's) of CFDN ranged from 0.20 to 2.12 micrograms/ml with 5% granules and from 0.50 to 1.15 micrograms/ml with 10% granules at 2 to 3 hours after dosing.","[Bacteriological, pharmacokinetic and clinical studies of 5% and 10% granules of cefdinir in the pediatric field]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1495196/),[μg] / [ml],0.50 to 1.15,263813,DB00535,Cefdinir
,1495196,peak concentrations,"At a dose of 6 mg/kg, peak concentrations were 0.66-2.06 micrograms/ml and 0.70-1.52 micrograms/ml with 5% granules and with 10% granules, respectively.","[Bacteriological, pharmacokinetic and clinical studies of 5% and 10% granules of cefdinir in the pediatric field]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1495196/),[μg] / [ml],0.66-2.06,263814,DB00535,Cefdinir
,1495196,peak concentrations,"At a dose of 6 mg/kg, peak concentrations were 0.66-2.06 micrograms/ml and 0.70-1.52 micrograms/ml with 5% granules and with 10% granules, respectively.","[Bacteriological, pharmacokinetic and clinical studies of 5% and 10% granules of cefdinir in the pediatric field]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1495196/),[μg] / [ml],0.70-1.52,263815,DB00535,Cefdinir
,1495196,blood concentrations,"At 8 hours after dosing, blood concentrations were 0.04-0.54 micrograms/ml at 3 mg/kg and 0.06-0.27 micrograms/ml at 6 mg/kg.","[Bacteriological, pharmacokinetic and clinical studies of 5% and 10% granules of cefdinir in the pediatric field]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1495196/),,0.04-0.54,263816,DB00535,Cefdinir
,1495196,blood concentrations,"At 8 hours after dosing, blood concentrations were 0.04-0.54 micrograms/ml at 3 mg/kg and 0.06-0.27 micrograms/ml at 6 mg/kg.","[Bacteriological, pharmacokinetic and clinical studies of 5% and 10% granules of cefdinir in the pediatric field]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1495196/),,0.06-0.27,263817,DB00535,Cefdinir
,1495196,Blood half-lives,Blood half-lives were 1.33-4.36 hours at 3 mg/kg and 1.14-3.27 hours at 6 mg/kg.,"[Bacteriological, pharmacokinetic and clinical studies of 5% and 10% granules of cefdinir in the pediatric field]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1495196/),h,1.33-4.36,263818,DB00535,Cefdinir
,1495196,Blood half-lives,Blood half-lives were 1.33-4.36 hours at 3 mg/kg and 1.14-3.27 hours at 6 mg/kg.,"[Bacteriological, pharmacokinetic and clinical studies of 5% and 10% granules of cefdinir in the pediatric field]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1495196/),h,1.14-3.27,263819,DB00535,Cefdinir
,1495196,AUC's,AUC's were 1.7-11.0 micrograms.hr/ml with 3 mg/kg and 2.4-8.7 micrograms.hr/ml with 6 mg/kg.,"[Bacteriological, pharmacokinetic and clinical studies of 5% and 10% granules of cefdinir in the pediatric field]. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1495196/),[h·μg] / [ml],1.7-11.0,263820,DB00535,Cefdinir
,1495196,AUC's,AUC's were 1.7-11.0 micrograms.hr/ml with 3 mg/kg and 2.4-8.7 micrograms.hr/ml with 6 mg/kg.,"[Bacteriological, pharmacokinetic and clinical studies of 5% and 10% granules of cefdinir in the pediatric field]. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1495196/),[h·μg] / [ml],2.4-8.7,263821,DB00535,Cefdinir
,1495196,Cmax's,"With administration of single 100 mg capsule, Cmax's, blood concentrations after 8 hours, T1/2's and AUC's were 0.79-1.88 micrograms/ml, 0.20 micrograms/ml, 1.54-2.72 hours, and 5.2 micrograms.hr/ml, respectively.","[Bacteriological, pharmacokinetic and clinical studies of 5% and 10% granules of cefdinir in the pediatric field]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1495196/),[μg] / [ml],0,263822,DB00535,Cefdinir
,1495196,blood concentrations after 8 hours,"With administration of single 100 mg capsule, Cmax's, blood concentrations after 8 hours, T1/2's and AUC's were 0.79-1.88 micrograms/ml, 0.20 micrograms/ml, 1.54-2.72 hours, and 5.2 micrograms.hr/ml, respectively.","[Bacteriological, pharmacokinetic and clinical studies of 5% and 10% granules of cefdinir in the pediatric field]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1495196/),[μg] / [ml],0.20,263823,DB00535,Cefdinir
,1495196,T1/2's,"With administration of single 100 mg capsule, Cmax's, blood concentrations after 8 hours, T1/2's and AUC's were 0.79-1.88 micrograms/ml, 0.20 micrograms/ml, 1.54-2.72 hours, and 5.2 micrograms.hr/ml, respectively.","[Bacteriological, pharmacokinetic and clinical studies of 5% and 10% granules of cefdinir in the pediatric field]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1495196/),[μg] / [ml],0.20,263824,DB00535,Cefdinir
,1495196,AUC's,"With administration of single 100 mg capsule, Cmax's, blood concentrations after 8 hours, T1/2's and AUC's were 0.79-1.88 micrograms/ml, 0.20 micrograms/ml, 1.54-2.72 hours, and 5.2 micrograms.hr/ml, respectively.","[Bacteriological, pharmacokinetic and clinical studies of 5% and 10% granules of cefdinir in the pediatric field]. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1495196/),[h·μg] / [ml],5.2,263825,DB00535,Cefdinir
,1495196,Urinary recovery rates,Urinary recovery rates in the first 8 hours ranged from 6.85 to 39.2% with 3 mg/kg and 6.08-25.5% with 6 mg/kg.,"[Bacteriological, pharmacokinetic and clinical studies of 5% and 10% granules of cefdinir in the pediatric field]. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1495196/),%,6.85 to 39.2,263826,DB00535,Cefdinir
,1495196,Urinary recovery rates,Urinary recovery rates in the first 8 hours ranged from 6.85 to 39.2% with 3 mg/kg and 6.08-25.5% with 6 mg/kg.,"[Bacteriological, pharmacokinetic and clinical studies of 5% and 10% granules of cefdinir in the pediatric field]. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1495196/),%,6.08-25.5,263827,DB00535,Cefdinir
,9748717,Cmax,"Cmax values were 1.64-4.34 micrograms/ml, t1/2 values were 10.8-21.9 h., and AUC values were 31.1-73.1 micrograms.h/ml (0-30 h) in four patients given a single oral dose of 100 mg of cefdinir as a capsule.",Pharmacokinetics of cefdinir and its transfer to dialysate in patients with chronic renal failure undergoing continuous ambulatory peritoneal dialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9748717/),[μg] / [ml],1.64-4.34,265943,DB00535,Cefdinir
,9748717,t1/2,"Cmax values were 1.64-4.34 micrograms/ml, t1/2 values were 10.8-21.9 h., and AUC values were 31.1-73.1 micrograms.h/ml (0-30 h) in four patients given a single oral dose of 100 mg of cefdinir as a capsule.",Pharmacokinetics of cefdinir and its transfer to dialysate in patients with chronic renal failure undergoing continuous ambulatory peritoneal dialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9748717/),h,10.8-21.9,265944,DB00535,Cefdinir
,9748717,AUC,"Cmax values were 1.64-4.34 micrograms/ml, t1/2 values were 10.8-21.9 h., and AUC values were 31.1-73.1 micrograms.h/ml (0-30 h) in four patients given a single oral dose of 100 mg of cefdinir as a capsule.",Pharmacokinetics of cefdinir and its transfer to dialysate in patients with chronic renal failure undergoing continuous ambulatory peritoneal dialysis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9748717/),[h·μg] / [ml],31.1-73.1,265945,DB00535,Cefdinir
,2086815,Peak plasma levels,"Peak plasma levels of 0.71 microgram/ml, 0.78 microgram/ml and 0.45 microgram/ml were attained in the 3 children, respectively, at 4 hours after dosing.",[Pharmacokinetic and clinical studies of cefdinir in pediatric field]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2086815/),[μg] / [ml],0.71,267349,DB00535,Cefdinir
,2086815,Peak plasma levels,"Peak plasma levels of 0.71 microgram/ml, 0.78 microgram/ml and 0.45 microgram/ml were attained in the 3 children, respectively, at 4 hours after dosing.",[Pharmacokinetic and clinical studies of cefdinir in pediatric field]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2086815/),[μg] / [ml],0.78,267350,DB00535,Cefdinir
,2086815,Peak plasma levels,"Peak plasma levels of 0.71 microgram/ml, 0.78 microgram/ml and 0.45 microgram/ml were attained in the 3 children, respectively, at 4 hours after dosing.",[Pharmacokinetic and clinical studies of cefdinir in pediatric field]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2086815/),[μg] / [ml],0.45,267351,DB00535,Cefdinir
,2086815,Half-lives,"Half-lives of CFDN in serum were 1.78 hours, 1.48 hours and 2.23 hours, respectively.",[Pharmacokinetic and clinical studies of cefdinir in pediatric field]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2086815/),h,1.78,267352,DB00535,Cefdinir
,2086815,Half-lives,"Half-lives of CFDN in serum were 1.78 hours, 1.48 hours and 2.23 hours, respectively.",[Pharmacokinetic and clinical studies of cefdinir in pediatric field]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2086815/),h,1.48,267353,DB00535,Cefdinir
,2086815,Half-lives,"Half-lives of CFDN in serum were 1.78 hours, 1.48 hours and 2.23 hours, respectively.",[Pharmacokinetic and clinical studies of cefdinir in pediatric field]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2086815/),h,2.23,267354,DB00535,Cefdinir
,2086815,urinary recovery rates,"The 12-hour urinary recovery rates of CFDN were 17.4%, 28.1% and 6.2%.",[Pharmacokinetic and clinical studies of cefdinir in pediatric field]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2086815/),%,17.4,267355,DB00535,Cefdinir
,2086815,urinary recovery rates,"The 12-hour urinary recovery rates of CFDN were 17.4%, 28.1% and 6.2%.",[Pharmacokinetic and clinical studies of cefdinir in pediatric field]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2086815/),%,28.1,267356,DB00535,Cefdinir
,2086815,urinary recovery rates,"The 12-hour urinary recovery rates of CFDN were 17.4%, 28.1% and 6.2%.",[Pharmacokinetic and clinical studies of cefdinir in pediatric field]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2086815/),%,6.2,267357,DB00535,Cefdinir
,2086815,T 1/2,T 1/2 was 1.78 hours.,[Pharmacokinetic and clinical studies of cefdinir in pediatric field]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2086815/),h,1.78,267358,DB00535,Cefdinir
,2086815,urinary recovery rate,The 12-hour urinary recovery rate of CFDN was 15.0%.,[Pharmacokinetic and clinical studies of cefdinir in pediatric field]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2086815/),h,12,267359,DB00535,Cefdinir
,2086815,urinary recovery rate,The 12-hour urinary recovery rate of CFDN was 15.0%.,[Pharmacokinetic and clinical studies of cefdinir in pediatric field]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2086815/),%,15.0,267360,DB00535,Cefdinir
,8849263,half-life,Captopril increased the cefdinir half-life from 0.62 +/- 0.17 to 2.92 +/- 0.95 h.,Pharmacokinetic interaction between cefdinir and two angiotensin-converting enzyme inhibitors in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8849263/),h,0.62,269692,DB00535,Cefdinir
,8849263,half-life,Captopril increased the cefdinir half-life from 0.62 +/- 0.17 to 2.92 +/- 0.95 h.,Pharmacokinetic interaction between cefdinir and two angiotensin-converting enzyme inhibitors in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8849263/),h,2.92,269693,DB00535,Cefdinir
